var title_f1_39_1648="Aspergillus lung abscess PA";
var content_f1_39_1648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lung abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Aspergillus fumigatus lung abscess in a liver transplant recipient. The patient had recently purchased a farm, leading to extensive exposure to soil-borne pathogens; the patient subsequently developed cryptococcosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jay Fishman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1648=[""].join("\n");
var outline_f1_39_1648=null;
var title_f1_39_1649="Thyroid colloid FNA";
var content_f1_39_1649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colloid from a macrofollicular nodule: Findings on fine needle aspirate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Papanicolaou stain showing colloid which is usually abundant in the background of macrofollicular lesions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1649=[""].join("\n");
var outline_f1_39_1649=null;
var title_f1_39_1650="Patient information: Morning sickness (The Basics)";
var content_f1_39_1650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/55/23411\">",
"         Patient information: Pregnancy symptoms (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/63/37874\">",
"         Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Morning sickness (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/morning-sickness-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H214835670\">",
"      <span class=\"h1\">",
"       What is morning sickness?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Morning sickness is the nausea and vomiting (throwing up) that many women have during pregnancy. Symptoms can be mild or severe. Even though it is called &ldquo;morning&rdquo; sickness, symptoms can happen any time of day. In fact, most women who have the condition feel sick all day long. Morning sickness usually gets better after the first few months of pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835677\">",
"      <span class=\"h1\">",
"       Do all pregnant women get morning sickness?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But it&rsquo;s very common. As many as 9 out of 10 pregnant women feel nauseous early in pregnancy. A smaller number actually throw up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835684\">",
"      <span class=\"h1\">",
"       When does morning sickness happen?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on the woman and the pregnancy. Symptoms usually start during the first 2 months of pregnancy. They are often worst around the second and third months. Most women feel better by 4 or 5 months, or around the middle of pregnancy. But some women feel bad for much longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835691\">",
"      <span class=\"h1\">",
"       What causes morning sickness?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors aren&rsquo;t sure why pregnancy sometimes causes nausea and vomiting, or why some women have more nausea and vomiting than others.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835698\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Throw up every day or throw up over and over during the day. This is even more of a concern if there is blood in your vomit.",
"       </li>",
"       <li>",
"        Are losing weight",
"       </li>",
"       <li>",
"        Have pain or cramps in your belly",
"       </li>",
"       <li>",
"        Think you have lost too many fluids. This is called dehydration. Signs include not urinating very much, having dark yellow urine, or feeling dizzy when you stand up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you can&rsquo;t keep anything down, you might need to be given fluids through a tube that is put into one of your veins, called an &ldquo;IV.&rdquo; Plus, you might need to get a medicine to prevent nausea and vomiting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835705\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your symptoms aren&rsquo;t too serious, you can try:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eating as soon as you feel hungry, or even before you feel hungry",
"       </li>",
"       <li>",
"        Snacking often and eating small meals. The best foods to eat have lots of protein or carbohydrates, but not a lot of fat. Good choices are crackers, bread, and low-fat yogurt. You should also avoid spicy foods.",
"       </li>",
"       <li>",
"        Drinking cold, clear beverages that are either fizzy or sour. Good choices are lemonade and ginger ale.",
"       </li>",
"       <li>",
"        Eating ginger flavored lollipops",
"       </li>",
"       <li>",
"        Smelling fresh lemon, mint, or orange",
"       </li>",
"       <li>",
"        Brushing your teeth right after you eat",
"       </li>",
"       <li>",
"        Not lying down right after you eat",
"       </li>",
"       <li>",
"        Taking your vitamins at bedtime with a snack, not in the morning",
"       </li>",
"       <li>",
"        Avoiding things that make you feel nauseous. That might include stuffy rooms, strong smells, hot places, loud noises, or not sleeping enough.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835712\">",
"      <span class=\"h1\">",
"       Are there medicines I can take?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are medicines that can help with nausea and vomiting. Some are safe to take while pregnant. Talk with your doctor before taking anything. He or she might suggest:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vitamin B6",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/47/14068?source=see_link\">",
"         Doxylamine",
"        </a>",
"        (sold as Unisom&reg; or Good Sense Sleep Aid&reg;) &ndash; Doctors sometimes suggest taking doxylamine together with vitamin B6.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/60/25537?source=see_link\">",
"         Diphenhydramine",
"        </a>",
"        (sold as Benadryl&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?13/33/13844?source=see_link\">",
"         meclizine",
"        </a>",
"        (sold as Dramamine&reg;) &ndash; These medicines can make you sleepy.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are also bands that you can wear on your wrists called &ldquo;acupressure&rdquo; bands. These bands are supposed to reduce morning or motion sickness. Some women feel better if they wear them. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835719\">",
"      <span class=\"h1\">",
"       Can morning sickness be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors urge all women who might get pregnant and who are pregnant to take vitamins. The vitamin should contain 400 micrograms of",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      . Taking vitamins before pregnancy and in early pregnancy might decrease nausea and vomiting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835726\">",
"      <span class=\"h1\">",
"       Will morning sickness hurt my baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your baby will probably be fine. It is OK to gain weight slowly in the beginning of your pregnancy. Most women should gain between 25 and 35 pounds by the end. Even women with the worst symptoms usually have healthy babies.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214835733\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=see_link\">",
"       Patient information: Pregnancy symptoms (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/63/37874?source=see_link\">",
"       Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?1/39/1650?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15614 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-A7B55BFC08-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1650=[""].join("\n");
var outline_f1_39_1650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835670\">",
"      What is morning sickness?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835677\">",
"      Do all pregnant women get morning sickness?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835684\">",
"      When does morning sickness happen?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835691\">",
"      What causes morning sickness?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835698\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835705\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835712\">",
"      Are there medicines I can take?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835719\">",
"      Can morning sickness be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835726\">",
"      Will morning sickness hurt my baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214835733\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/63/37874?source=related_link\">",
"      Patient information: Nausea and vomiting of pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/55/23411?source=related_link\">",
"      Patient information: Pregnancy symptoms (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_39_1651="Erythema migrans - close view";
var content_f1_39_1651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Erythema migrans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large inflammatory plaque with an annular configuration is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1651=[""].join("\n");
var outline_f1_39_1651=null;
var title_f1_39_1652="Role of the Wnt signaling pathway";
var content_f1_39_1652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Role of the Wnt signaling pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wnt signaling diverts the mesenchymal stem cells down the pathway of osteoblast differentiation. DKK-1 binds to the Wnt receptor complex on the surface of the osteoblast lineage cell and blocks Wnt signaling, arresting osteoblast proliferation and differentiation. The precursors of the mature osteoblast enhance bone resorption by boosting RANKL-induced osteoclastogenesis. Blockade of DKK-1 permits progression of osteoblast differentiation. Activation of the Wnt signaling pathway in the mature osteoblast upregulates OPG, which blocks RANKL-induced osteoclastogenesis, resulting in inhibition of bone resorption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007; 13:133. Copyright &copy; 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1652=[""].join("\n");
var outline_f1_39_1652=null;
var title_f1_39_1653="Adenoid cystic carcinoma CT";
var content_f1_39_1653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenoid cystic carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 525px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomographic scans often reveal an irregular tracheal mass that originates from the posterior wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1653=[""].join("\n");
var outline_f1_39_1653=null;
var title_f1_39_1654="Synthetic conjugated estrogens A: Patient drug information";
var content_f1_39_1654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Synthetic conjugated estrogens A: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/28/32199?source=see_link\">",
"     see \"Synthetic conjugated estrogens A: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cenestin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3275368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cenestin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Estrogens, when used in women after stopping periods (menopause), may raise the chance of uterine cancer. Progestins may lower this chance. A warning sign for cancer of the uterus is vaginal bleeding. Report any vaginal bleeding to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens if you are pregnant. If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take estrogens to stop heart disease or dementia. Using estrogens may raise your chances of having a heart attack, a stroke, breast cancer, or a blood clot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to estrogen, conjugated, A (synthetic) or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, liver disease, recent heart attack, recent stroke, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697661",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There may be a higher chance of endometrial or breast cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had high triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have porphyria, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11726 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1654=[""].join("\n");
var outline_f1_39_1654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3275368\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027392\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027394\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027393\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027398\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027399\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027401\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027396\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027397\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027402\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027403\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/28/32199?source=related_link\">",
"      Synthetic conjugated estrogens A: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_39_1655="Steroid responsive autoimmune chronic hepatitis - high power";
var content_f1_39_1655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Steroid responsive autoimmune chronic hepatitis (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Interface hepatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1655=[""].join("\n");
var outline_f1_39_1655=null;
var title_f1_39_1656="Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy";
var content_f1_39_1656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rising serum PSA after radiation therapy for localized prostate cancer: Salvage local therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1656/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1656/contributors\">",
"     Judd W Moul, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1656/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1656/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1656/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1656/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1656/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/39/1656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 17, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate specific antigen (PSA) is a sensitive and specific marker for prostate tissue, and serum PSA is elevated in 95 percent of men with advanced prostate cancer. Due to the sensitivity of serum PSA, serial measurements are routinely obtained to detect early disease recurrence in men who have been treated for localized disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=see_link\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring PSA after treatment of localized prostate cancer leads to the identification of men with a PSA-only (biochemical) recurrence. In this situation, increases in serum PSA over the baseline after initial treatment are not accompanied by symptoms or signs of locally recurrent or metastatic disease. Many of these men are relatively young and otherwise healthy. For men in whom there is a significant likelihood that disease is confined to the prostatic bed, salvage therapy may result in prolonged disease-free survival.",
"   </p>",
"   <p>",
"    The role of definitive salvage therapy after initial radiation therapy (external beam or brachytherapy) is reviewed here. Other aspects of patient management for men with a rising serum PSA following initial RT are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=see_link\">",
"       \"Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=see_link\">",
"       \"Rising serum PSA after treatment for localized prostate cancer: Systemic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81458203\">",
"    <span class=\"h1\">",
"     DEFINITION OF BIOCHEMICAL FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpretation of changes in serum PSA after RT can be difficult since some normal prostatic glandular tissue is present. Thus, serum PSA levels are unlikely to fall to undetectable levels following a course of RT.",
"   </p>",
"   <p>",
"    The most widely accepted definition is the so-called Phoenix criteria, established by the American Society for Radiation Oncology (ASTRO) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/1\">",
"     1",
"    </a>",
"    ]. According to this definition, a PSA rise of 2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or more above the nadir PSA is considered a biochemical failure in a man previously treated RT, with or without androgen deprivation therapy (ADT). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H6#H6\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Radiation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal criteria have not been established to determine which men are candidates for local salvage therapy following a PSA-only recurrence. The decision of whether or not to proceed to local salvage therapy is based upon the likelihood that disease is locally confined combined with an assessment of the patient's age and overall health. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical and pathologic parameters at the time of original diagnosis, as well as subsequent events, are helpful in predicting those men who are most likely to develop distant metastases despite local therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who were classified as high-risk at their original presentation are at increased risk for developing distant disease following initial therapy and are less likely to benefit from local salvage therapy. In particular, this includes men who had a Gleason score &ge;8, a clinical tumor stage &ge;T2c, or a serum PSA level &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/2\">",
"       2",
"      </a>",
"      ]. This corresponds to anatomic stage prognostic groups IIB and III in the 2010 TNM staging system (",
"      <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A shorter interval from treatment to biochemical failure was significantly associated with an increase in prostate cancer specific mortality in a study of 1722 men treated with RT for prostate cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/3\">",
"       3",
"      </a>",
"      ]. The five-year prostate cancer specific mortality was significantly higher in those with an interval to biochemical failure &lt;18 months compared with an interval &gt;18 months (26 versus 9 percent).",
"     </li>",
"     <li>",
"      A short PSA doubling time following initial therapy is correlated with an increased risk of subsequent distant metastases. As an example, in one study, a PSA doubling time &lt;8 months was associated with a 54 percent risk of distant metastases at seven years, and in another report a PSA doubling time &lt;3 months correlated with a 49 percent risk of distant metastases at three years [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A serum PSA &gt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at the time of evaluation for salvage therapy correlates with a poorer outcome following therapy for a PSA-only recurrence with a lower serum PSA [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although long-term outcomes are better with early treatment for a PSA-only recurrence, these results may reflect the natural history of the disease and do not necessarily reflect a benefit from therapy. Men with a PSA-only relapse and relatively low PSA levels (particularly those with a low Gleason score, clinical stage T1 or T2 tumors, a long PSA doubling time, and a long interval to PSA recurrence) are more likely to have a prolonged disease course even without treatment. The lack of randomized trials comparing surgery or another form of local therapy versus observation makes it difficult to know whether these men would have remained free of clinical metastases even without salvage therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=see_link&amp;anchor=H10#H10\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aggressive local salvage therapy is associated with the risk of clinically significant toxicity and should not be undertaken unless there is biopsy confirmation of a local recurrence. There are no randomized trials that compare different therapeutic options (ie, radical prostatectomy, cryotherapy, brachytherapy) in this setting, and the choice of intervention should consider the available experience and expertise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RADICAL PROSTATECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salvage prostatectomy provides prolonged disease control in many patients. In the pre-PSA era, surgery was not widely used because of concerns about operative morbidity and frequent development of disseminated metastases. More contemporary experience, utilizing better patient selection criteria and improved operative techniques has made radical prostatectomy an important option for appropriately selected patients, particularly those with a life expectancy of 10 to 15 years or more [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/8\">",
"     8",
"    </a>",
"    ]. Although most of the literature is based upon open radical prostatectomy, minimally invasive techniques appear to be an option for experienced surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to surgery, appropriate studies should be conducted to rule out disseminated disease and to provide a tissue confirmation of the diagnosis of recurrence in the prostate bed. In men who are candidates for radical prostatectomy, cystoscopic examination is helpful to rule out bladder neck involvement or urethral strictures.",
"   </p>",
"   <p>",
"    The diagnostic evaluation of men with a biochemical failure after definitive local therapy for early prostate cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Disease control",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that compare radical prostatectomy with other local salvage therapy approaches or observation.",
"   </p>",
"   <p>",
"    Results from retrospective series in the PSA-era provide some insight into the ability of radical prostatectomy to control disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As an example, one series included 138 men who underwent salvage radical prostatectomy at the Mayo Clinic since PSA monitoring became routine. At a median follow-up of 92 months, the five-year failure-free survival rate was 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar results were seen in a series of 146 men managed at Memorial Sloan-Kettering, where the five-year recurrence-free survival rate was 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, men with disease confined to the prostate have better outcomes than those with either extraprostatic extension or seminal vesicle invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The status of the surgical margins is also a strong predictor of both disease-specific and disease-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported long-term outcomes following salvage radical prostatectomy are consistently better in men with low serum PSA levels (",
"    <a class=\"graphic graphic_table graphicRef52045 \" href=\"UTD.htm?4/12/4301\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/10,13,15,16\">",
"     10,13,15,16",
"    </a>",
"    ]. As an example, in a report of 100 consecutive men undergoing salvage prostatectomy after initial RT, five-year progression-free survival rates stratified by preoperative PSA level were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      &mdash; 86 percent",
"     </li>",
"     <li>",
"      4 to 10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      &mdash; 55 percent",
"     </li>",
"     <li>",
"      &gt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      &mdash; 28 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these results reflect an effect of treatment is uncertain. Men with a low serum PSA may have more indolent disease, and these men might have had a high likelihood of remaining free of clinical disease progression without surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older series of patients treated with salvage prostatectomy reported major complications in one-third to one-half of all men [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. These included rectal injury, bladder neck contractures, hemorrhage, ureteral injury, vesicorectal or vesicoperineal fistulas, venous thromboembolism, and chronic urinary incontinence.",
"   </p>",
"   <p>",
"    These series included many patients who had undergone staging pelvic lymph node dissection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    open radioactive seed implantation. The degree of fibrosis after modern conformal external beam RT or transperineal brachytherapy is much less, permitting the majority of men to undergo a salvage operation that is similar to the standard nonsalvage prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In three large contemporary series, the rate of early perioperative complications ranged from 13 to 27 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/10,12,15\">",
"     10,12,15",
"    </a>",
"    ]. A summary of acute and late complications in three contemporary salvage radical prostatectomy series is presented in the table (",
"    <a class=\"graphic graphic_table graphicRef59796 \" href=\"UTD.htm?21/57/22427\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H24077788#H24077788\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Complications and quality of life'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, late rates of urinary incontinence (30 to 70 percent) and anastomotic stricture (17 to 32 percent) do not appear to have improved substantially despite better patient selection, less pelvic fibrosis, and better surgical technique [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/15,21,22\">",
"     15,21,22",
"    </a>",
"    ]. These rates are substantially higher than those observed after radical prostatectomy as initial therapy. This may reflect the persistence of radiation-induced sphincter dysfunction. When the assessment is based upon patient-reported data, even higher rates of incontinence have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/20\">",
"     20",
"    </a>",
"    ]. The incidence of incontinence may also be biased by the use of an artificial urinary sphincter in some patients.",
"   </p>",
"   <p>",
"    Erectile dysfunction was previously thought to be an inevitable consequence of salvage prostatectomy. However, nerve preservation is often feasible, and some men with good preoperative erectile function may recover potency after bilateral nerve-sparing salvage prostatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/23\">",
"     23",
"    </a>",
"    ]. In one retrospective series, 45 percent of men who were potent preoperatively maintained potency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/20\">",
"     20",
"    </a>",
"    ], and men were more likely to recover erectile function if they had bilateral preservation of the neurovascular bundles [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Perioperative ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that address the role of adjuvant or neoadjuvant ADT in men undergoing salvage prostatectomy. Small retrospective series have reported on the use of perioperative ADT in this setting, but these reports do not provide reliable information on the efficacy of these approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/7,14,19\">",
"     7,14,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CRYOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with locally recurrent disease, cryoablation is less invasive than salvage prostatectomy and it may have curative potential. The rationale and techniques for prostate cryotherapy, as well as its use for the initial treatment of prostate cancer, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=see_link\">",
"     \"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85229518\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of salvage cryoablation following RT has been evaluated only in retrospective series. Many of these reports used older cryotherapy techniques, and their interpretation is further limited by variable definitions of biochemical failure.",
"   </p>",
"   <p>",
"    The most extensive data come from the Cryo On-Line Data (COLD) Registry, which reported on the results of 279 men who underwent cryotherapy for a recurrence following primary treatment with RT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/24\">",
"     24",
"    </a>",
"    ]. In this series the five-year biochemical disease-free survival rates were 59 and 55 percent, respectively, depending upon whether the ASTRO or Phoenix criteria were used. Among those who underwent a repeat biopsy following cryotherapy, 15 of 46 were positive (33 percent).",
"   </p>",
"   <p>",
"    The results with salvage cryotherapy are better when treatment is carried out in men with a relatively low PSA [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. This was illustrated by a series from the COLD registry, in which the 12 and 36 month biochemical progression-free survival rates were 80 and 67 percent, respectively, for men with a serum PSA less than 0.6",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    at the time of salvage cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast, of those with a PSA between 0.6 and 5.0",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    50 percent had relapsed by 12 months, and 64 percent of those with a PSA greater than 5",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    had relapsed by six months.",
"   </p>",
"   <p>",
"    However, the incidence of biochemical failure may be substantially higher if a more stringent criterion is applied. In a preliminary report from the M. D. Anderson Cancer Center, the long-term treatment outcomes of salvage cryotherapy for locally recurrent prostate cancer following primary radiotherapy were evaluated in a cohort of 110 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/28\">",
"     28",
"    </a>",
"    ]. Only 17 percent of patients had no evidence of biochemical failure at 10 years following salvage cryotherapy when successful treatment was defined as a PSA &lt;0.5",
"    <span class=\"nowrap\">",
"     ng/ml",
"    </span>",
"    following cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85229545\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can experience the same range of complications following salvage cryotherapy that have been observed when cryotherapy is used for the treatment of primary localized prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=see_link&amp;anchor=H11#H11\">",
"     \"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, the complications of salvage cryotherapy appear to be more common and more severe than with primary cryotherapy. These differences include the full array of potential cryotherapy complications. As with cryoablation for primary therapy of prostate cancer, effective urethral warming is essential for reducing complications and maximizing quality of life for men undergoing salvage cryoablation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the COLD registry series, urinary incontinence sufficient to require the use of pads was reported in 4 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the reported rates of incontinence were substantially higher in a study that relied upon patient, rather than physician, reporting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/30\">",
"     30",
"    </a>",
"    ]. Forty-six men undergoing salvage cryotherapy were asked to complete quality of life forms before and after therapy. Urinary bother was a moderate to big problem 24 months after cryotherapy in 29 percent; 73 percent reported leaking of urine daily or weekly and 53 percent needed one or more pads daily.",
"   </p>",
"   <p>",
"    The net effect is that salvage cryotherapy may not offer quality of life advantages compared with salvage prostatectomy in men with locally recurrent disease following RT [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the development of newer techniques that are associated with fewer complications may favorably alter this balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=see_link&amp;anchor=H85226595#H85226595\">",
"     \"Cryotherapy and other ablative techniques for the initial treatment of prostate cancer\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85229635\">",
"    <span class=\"h2\">",
"     Cryotherapy versus salvage prostatectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective studies that directly compare cryosurgery with radical prostatectomy or brachytherapy after failure of external beam RT.",
"   </p>",
"   <p>",
"    A retrospective study compared 42 men treated with salvage prostatectomy at the Mayo Clinic to 56 patients treated by salvage cryotherapy at M. D. Anderson Cancer Center. Patients were matched for pretreatment PSA and biopsy Gleason score [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/31\">",
"     31",
"    </a>",
"    ]. Biochemical progression occurred more frequently in patients treated with salvage cryotherapy than with radical prostatectomy (five-year bRFS 66 versus 42 percent, based upon a criterion of two increases in serum PSA above nadir). At a median follow-up of eight years, there was no difference in disease-specific survival (96 versus 98 percent). The choice of therapy needs to be individualized, and cryotherapy is appropriate for older patients and those with significant comorbidity.",
"   </p>",
"   <p>",
"    Cryotherapy can freeze and destroy tissue beyond the confines of the prostate gland, and this may be an advantage compared to radical prostatectomy for selected cases. Guidelines from the American Urological Association support cryotherapy as an option in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BRACHYTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another option that has been used for men with a biochemical recurrence following initial management with external beam RT is salvage brachytherapy. Brachytherapy is typically given by a low-dose rate methodology using iodine-125 (I-125) or palladium-103 (Pd-103) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/33-37\">",
"     33-37",
"    </a>",
"    ], but can also be given using a high-dose rate technique [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=see_link&amp;anchor=H3#H3\">",
"     \"Brachytherapy for localized prostate cancer\", section on 'Technique'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials comparing brachytherapy with other forms of salvage therapy. The results with brachytherapy are illustrated by the following retrospective observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series, 49 men with biopsy-proven local recurrence after external beam RT underwent salvage low-dose rate brachytherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/33\">",
"       33",
"      </a>",
"      ]. At 64 months average follow-up, the biochemical relapse-free survival rates at three and five years were 48 and 34 percent, respectively. Men whose PSA nadir was &lt;0.5",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      after salvage brachytherapy (47 percent of the cohort) fared better than those whose nadir was higher (five-year biochemical relapse-free survival 56 versus 15 percent, respectively).",
"     </li>",
"     <li>",
"      In the series with the longest follow-up, 37 men were treated with low-dose rate brachytherapy after initial RT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/35\">",
"       35",
"      </a>",
"      ]. At a median follow-up of seven years, the ten-year freedom from biochemical failure and cancer specific survival rates were 54 and 96 percent, respectively.",
"     </li>",
"     <li>",
"      In the largest series using high-dose rate brachytherapy, 21 men were treated for recurrent prostate cancer after external beam RT [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1656/abstract/38\">",
"       38",
"      </a>",
"      ]. At a median follow-up of 19 months, 13 had achieved a PSA nadir of &le;0.1",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      There were two biochemical failures, both of which occurred in the setting of distant metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these limited results suggest that salvage brachytherapy has promise, further study is required. Although brachytherapy should not be considered a standard approach for men with a local recurrence after external beam RT, this may be an appropriate option when treatment is given by a brachytherapist with appropriate expertise at an experienced center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The routine monitoring of serum PSA after treatment of early stage prostate cancer has led to the identification of men with a PSA-only (biochemical) recurrence without symptoms or signs or locally recurrent or disseminated prostate cancer. The most widely accepted definition of biochemical failure following radiation therapy (RT) is the Phoenix criteria. According to this definition, a PSA rise of 2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or more above the nadir PSA following definitive radiation therapy (external beam or brachytherapy) is considered a biochemical failure. (See",
"      <a class=\"local\" href=\"#H81458203\">",
"       'Definition of biochemical failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Men meeting the Phoenix criteria for biochemical recurrence should only be considered for salvage therapy in the absence of disseminated disease and after tissue confirmation of recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link\">",
"       \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with a positive prostate biopsy and no evidence of disseminated disease after definitive RT as their initial treatment, there are no clinical trials that define the optimal therapeutic approach. Options include observation, androgen deprivation therapy (ADT), radical prostatectomy, cryotherapy, or brachytherapy in patients previously treated with external beam RT. Key factors in choosing an approach include age, comorbidity, and patient preferences.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/1\">",
"      Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/2\">",
"      Nguyen PL, D'Amico AV, Lee AK, Suh WW. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007; 110:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/3\">",
"      Buyyounouski MK, Pickles T, Kestin LL, et al. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. J Clin Oncol 2012; 30:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/4\">",
"      Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 1997; 44:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/5\">",
"      Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005; 23:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/6\">",
"      de la Taille A, Hayek O, Benson MC, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology 2000; 55:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/7\">",
"      Tiguert R, Rigaud J, Lacombe L, et al. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol 2003; 170:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/8\">",
"      Chade DC, Eastham J, Graefen M, et al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur Urol 2012; 61:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/9\">",
"      Kaffenberger SD, Keegan KA, Bansal NK, et al. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J Urol 2013; 189:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/10\">",
"      Ward JF, Sebo TJ, Blute ML, Zincke H. Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes. J Urol 2005; 173:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/11\">",
"      Paparel P, Cronin AM, Savage C, et al. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur Urol 2009; 55:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/12\">",
"      Gheiler EL, Tefilli MV, Tiguert R, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 1998; 51:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/13\">",
"      Sanderson KM, Penson DF, Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006; 176:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/14\">",
"      Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. J Urol 1998; 159:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/15\">",
"      Bianco FJ Jr, Scardino PT, Stephenson AJ, et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/16\">",
"      Amling CL, Lerner SE, Martin SK, et al. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999; 161:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/17\">",
"      Rogers E, Ohori M, Kassabian VS, et al. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol 1995; 153:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/18\">",
"      Moul JW, Paulson DF. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991; 68:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/19\">",
"      Lerner SE, Blute ML, Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995; 154:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/20\">",
"      Stephenson AJ, Scardino PT, Bianco FJ Jr, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004; 172:2239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/21\">",
"      Stephenson AJ, Eastham JA. Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy. J Clin Oncol 2005; 23:8198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/22\">",
"      Gotto GT, Yunis LH, Vora K, et al. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 2010; 184:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/23\">",
"      Masterson TA, Stephenson AJ, Scardino PT, Eastham JA. Recovery of erectile function after salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Urology 2005; 66:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/24\">",
"      Pisters LL, Rewcastle JC, Donnelly BJ, et al. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008; 180:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/25\">",
"      Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol 2007; 178:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/26\">",
"      Bahn DK, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer 2003; 2:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/27\">",
"      Levy DA, Pisters LL, Jones JS. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int 2010; 106:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/28\">",
"      Hamoui O, Wiegand L, Bossier J, et al. Ten-year treatment outcomes of salvage cryotherapy for locally recurrent prostate cancer. J Urol 2008; 179:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/29\">",
"      Perrotte P, Litwin MS, McGuire EJ, et al. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol 1999; 162:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/30\">",
"      Robinson JW, Donnelly BJ, Coupland K, et al. Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol Oncol 2006; 24:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/31\">",
"      Pisters LL, Leibovici D, Blute M, et al. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009; 182:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/32\">",
"      Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008; 180:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/33\">",
"      Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999; 53:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/34\">",
"      Aaronson DS, Yamasaki I, Gottschalk A, et al. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009; 104:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/35\">",
"      Burri RJ, Stone NN, Unger P, Stock RG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 77:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/36\">",
"      Nguyen PL, Chen MH, D'Amico AV, et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007; 110:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/37\">",
"      Lee HK, Adams MT, Motta J. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy. Brachytherapy 2008; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1656/abstract/38\">",
"      Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007; 67:1106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6932 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1656=[""].join("\n");
var outline_f1_39_1656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81458203\">",
"      DEFINITION OF BIOCHEMICAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RADICAL PROSTATECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Disease control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Perioperative ADT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CRYOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85229518\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85229545\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85229635\">",
"      Cryotherapy versus salvage prostatectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BRACHYTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 1\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 2\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/12/4301\" title=\"table 3\">",
"      Results salv surg prost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/57/22427\" title=\"table 4\">",
"      Complic salvage surg prostat CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32824?source=related_link\">",
"      Brachytherapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/63/43000?source=related_link\">",
"      Cryotherapy and other ablative techniques for the initial treatment of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/48/30470?source=related_link\">",
"      Rising serum PSA after treatment for localized prostate cancer: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33544?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Definition, natural history, and risk stratification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/0/38918?source=related_link\">",
"      Rising serum PSA following radical prostatectomy for prostate cancer: Salvage radiation therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_39_1657="Pathophysiology and etiology of edema in children";
var content_f1_39_1657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology and etiology of edema in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1657/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1657/contributors\">",
"     Rudolph P Valentini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1657/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1657/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1657/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/39/1657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema is a clinical condition characterized by an increase in interstitial fluid volume and tissue swelling that can either be localized or generalized. Severe generalized edema is known as anasarca. More localized interstitial fluid collections include ascites and pleural effusions.",
"   </p>",
"   <p>",
"    Optimizing the diagnostic approach to edema is based upon a thoughtful approach to the pathogenesis of its formation. Once a diagnosis is established, specific treatment of the underlying disorder can be given. If specific therapy is not available, general treatment, such as fluid management, can be provided.",
"   </p>",
"   <p>",
"    The pediatric disease processes associated with edema and the pathogenesis of edema will be described in this topic review. More detailed discussions of evaluation and management of edema in children as well as the pathophysiology of edema are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7288?source=see_link\">",
"     \"Evaluation and management of edema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema does not occur in normal subjects because of the tight balance of hemodynamic forces along the capillary wall and the intact function of the lymphatic system. While capillary hydrostatic pressure favors transcapillary fluid movement into the interstitium, the colloid oncotic pressure across the capillary favors the retention of fluid within the vessel (",
"    <a class=\"graphic graphic_figure graphicRef55674 \" href=\"UTD.htm?14/10/14507\">",
"     figure 1",
"    </a>",
"    ). Under normal circumstances, these competing forces result in a small net movement of fluid into the interstitium. The lymphatic vessels return this interstitial fluid to the venous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology of edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following physiologic processes result in edema formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An alteration in capillary hemodynamics that favors increased movement of fluid from the vascular space into the interstitium",
"     </li>",
"     <li>",
"      Failure of interstitial fluid to be returned to the central venous system through the lymphatic vessels",
"     </li>",
"     <li>",
"      The retention of dietary or intravenously administered sodium and water by the kidneys, resulting in hypervolemia and increased vascular hydrostatic pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Altered capillary hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Movement of fluid from the vascular space into the interstitium requires a change in one or more components of Starling's law:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased capillary hydrostatic pressure",
"     </li>",
"     <li>",
"      Decreased capillary oncotic pressure",
"     </li>",
"     <li>",
"      Increased capillary permeability",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Impaired lymphatic transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of the return of interstitial fluid into the central vascular system through the lymphatic system is due to abnormal development, dysfunction, or obstruction of the lymphatic system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Renal salt and water retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal retention of sodium and water can either be a primary event (as in renal failure) or a secondary event resulting from a primary reduction in cardiac output (as in heart failure), or systemic vascular resistance (as in cirrhosis). In the latter setting, fluid retention is an appropriate response to return the effective circulating volume toward normal. In these patients, diuretic therapy may have a deleterious effect on systemic hemodynamics even though it reduces the edema.",
"   </p>",
"   <p>",
"    The increased salt and water retention leads to hypervolemia and increased capillary hydrostatic pressure (as in glomerulonephritis).",
"   </p>",
"   <p>",
"    The pathophysiology and etiology of edema and regulation of effective circulatory volume are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=see_link\">",
"     \"Pathophysiology and etiology of edema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H96014906#H96014906\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Regulation of effective arterial blood volume'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link&amp;anchor=H10#H10\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\", section on 'Edema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of edema in children produce either localized or generalized edema. As examples, a common cause of localized edema is venous obstruction from venous compression, and for generalized edema, nephrosis. The etiology of edema can also be classified by pathogenesis. The following section is a review of the most common causes of edema in children based on pathogenesis (",
"    <a class=\"graphic graphic_table graphicRef68106 \" href=\"UTD.htm?2/56/2957\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Increased hydrostatic pressure from sodium and water retention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure can present with edema due to an increase in venous pressure from sodium and water retention. This produces a parallel rise in capillary hydraulic pressure with increased transcapillary movement of fluid into the interstitial space. The site of edema accumulation is variable and is dependent upon the nature of the cardiac disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with impaired left ventricular function may present with pulmonary, but not peripheral, edema.",
"     </li>",
"     <li>",
"      Pure right ventricular failure may result in prominent edema in the lower extremities.",
"     </li>",
"     <li>",
"      Cardiomyopathies, which are associated with impaired function of both the right and left ventricles, may often lead to the simultaneous onset of pulmonary and peripheral edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical signs of heart failure in the older child include tachycardia, tachypnea, rales or wheezes, gallop rhythm, hepatomegaly, and edema. Although facial edema can be seen with right ventricular failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/1\">",
"     1",
"    </a>",
"    ], peripheral edema is generally less commonly observed in children with heart failure than in adults. Peripheral edema is unusual in young infants with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=see_link\">",
"     \"Etiology and diagnosis of heart failure in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acute glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Edema resulting from acute glomerulonephritis (AGN) can be either generalized or localized. The edema is primarily due to renal sodium and water retention.",
"   </p>",
"   <p>",
"    In addition to edema, clinical findings include hypertension, hematuria and proteinuria, cola-colored urine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    azotemia. Not all of these features are present in each patient. As an example, cola-colored urine, which is considered a classic feature of AGN, is present in only 30 to 50 percent of children [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/3\">",
"     3",
"    </a>",
"    ]. The finding of red cell casts, even if only one is seen, is virtually diagnostic of glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=see_link\">",
"     \"Evaluation of a child with glomerular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AGN can arise from a number of causes (",
"    <a class=\"graphic graphic_table graphicRef53697 \" href=\"UTD.htm?41/33/42523\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common cause of AGN is postinfectious glomerulonephritis, usually caused by a recent streptococcal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"       \"Poststreptococcal glomerulonephritis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other causes of primary AGN include IgA nephropathy, hereditary nephritis (also known as Alport syndrome), and membranoproliferative glomerulonephritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"       \"Clinical presentation and diagnosis of IgA nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=see_link\">",
"       \"Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Systemic diseases associated with glomerulonephritis include systemic lupus erythematosus (SLE), Henoch Sch&ouml;nlein purpura (HSP, also called IgA vasculitis [IgAV]), antineutrophil cytoplasmic autoantibody (ANCA) associated diseases such as granulomatosis with polyangiitis (formerly called Wegener granulomatosis) and microscopic polyangiitis, and anti-glomerular basement membrane (anti-GBM) disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"       \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=see_link\">",
"       \"Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serum C3 level is a useful diagnostic test in determining the etiology of AGN, as the causes of AGN can be classified as either hypocomplementemic or normocomplementemic (",
"    <a class=\"graphic graphic_table graphicRef53697 \" href=\"UTD.htm?41/33/42523\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with either acute or chronic renal failure can present with edema due to renal retention of sodium and water. The evaluation and diagnosis of the many different causes of acute or chronic renal failure is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihypertensive agents that are potent vasodilators cause renal sodium and water retention leading to increased hydrostatic pressure. These medications include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31472?source=see_link\">",
"     minoxidil",
"    </a>",
"    and the dihydropyridine calcium channel blockers (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/22/36199?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/48/8966?source=see_link\">",
"     felodipine",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     nicardipine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Increased capillary hydrostatic pressure from obstruction",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Venous obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized edema from venous obstruction arises from extrinsic venous compression, thrombosis, or congestion. Regardless of the cause of venous obstruction, the edema that develops occurs distal to the site of obstruction. As an example, symptomatic thrombosis in the inferior vena cava (IVC) typically presents as swelling of the lower limbs and lower body. By comparison, superior vena cava (SVC) thrombosis typically presents as swelling of the arm, neck, and head [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/5\">",
"     5",
"    </a>",
"    ]. The severity of the swelling depends upon the size of the thrombus and the degree of alternative collateral venous pathways. Often, thrombophlebitis is present with tenderness, swelling, and occasionally, a palpable cord.",
"   </p>",
"   <p>",
"    There are a large number of causes of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    risk factors for venous thrombosis in children. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Venous catheters (particularly in the newborn)",
"     </li>",
"     <li>",
"      Cyanotic congenital heart disease",
"     </li>",
"     <li>",
"      Vasculitis",
"     </li>",
"     <li>",
"      Hyperviscosity states (eg, polycythemia or sickle cell disease)",
"     </li>",
"     <li>",
"      Medications (eg, oral contraceptives)",
"     </li>",
"     <li>",
"      Immobilization",
"     </li>",
"     <li>",
"      Malignancies",
"     </li>",
"     <li>",
"      Systemic diseases (eg, nephrotic syndrome and SLE)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic predisposing factors including disorders of protein C, protein S, anti-thrombin III, Factor V Leiden, and homocystinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"     \"Protein C deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"     \"Protein S deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis and clinical manifestations of venous thromboembolism in children, infants, and neonates are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cirrhosis is defined as irreversible hepatic parenchymal injury with fibrosis of the liver. Children with cirrhosis can develop portal hypertension with an increase in venous pressure below the diseased liver, resulting in ascites and lower extremity edema.",
"   </p>",
"   <p>",
"    Although cirrhosis is relatively uncommon in children, the disorder can be caused by genetic disorders (alpha-1 antitrypsin deficiency, cystic fibrosis, Wilson's disease), infectious etiologies (viral hepatitis), and structural problems of the biliary tree (biliary atresia, Alagille syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=see_link\">",
"     \"Approach to neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Decreased capillary oncotic pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoalbuminemia results in a decrease in capillary oncotic pressure that favors the movement of fluid from the vascular to interstitial compartment. Hypoalbuminemia is seen in liver failure, protein malnutrition, protein losing enteropathy, and nephrotic syndrome, and it contributes to edema formation in all of these diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Protein malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe protein malnutrition or kwashiorkor can cause insufficient albumin synthesis resulting in hypoalbuminemia. This rarely occurs in developed countries. It should be considered in a child with generalized edema, skin rash over the scalp and extremities, and hypopigmentation of the hair (eg, red hair in a child who should have dark hair) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=see_link\">",
"     \"Malnutrition in developing countries: Clinical assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Protein losing enteropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with protein losing enteropathy have severe protein loss through the gut, resulting in low plasma protein levels (hypoalbuminemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/8\">",
"     8",
"    </a>",
"    ]. Causes include hypertrophic gastritis (M&eacute;n&eacute;trier's disease), milk protein allergy, celiac disease, inflammatory bowel disease, giardiasis, intestinal lymphangiectasia, and right sided heart dysfunction (post-Fontan procedure) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stool level of alpha-1 antitrypsin is an excellent screening test for protein losing enteropathy, as alpha-1 antitrypsin is a nondietary, serum protein synthesized in the liver. Its molecular weight of 50 kDa is similar in size to albumin (67 kDa), and it is resistant to intestinal and proteolytic digestion distal to the stomach.",
"   </p>",
"   <p>",
"    The clinical manifestation and diagnosis of this disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Increased capillary permeability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in capillary wall permeability are mediated by intrinsic factors, including cytokines (such as tumor necrosis factor and interleukins) and other vasodilators including histamine, bradykinin, prostaglandins, and complement factors (eg, C2a); and extrinsic factors (eg, pit viper venom).",
"   </p>",
"   <p>",
"    Generalized edema from increased capillary permeability most often occurs in patients with burns or sepsis. A rare cause is idiopathic systemic capillary leak syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/426?source=see_link\">",
"     \"Idiopathic systemic capillary leak syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to generalized edema, a variety of clinical settings (eg, allergic reactions and infections) result in the local release of these inflammatory factors leading to localized increased capillary permeability and movement of fluid from the vascular space into the interstitium. This condition is referred to as angioedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Angioedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioedema is associated with swelling of the deep layers of the cutaneous or submucosal tissues due to increased capillary permeability. Affected regions are usually the face, lips, tongue, or larynx.",
"   </p>",
"   <p>",
"    Angioedema can be distinguished clinically from generalized edema by the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relatively rapid onset of presentation (minutes to hours)",
"     </li>",
"     <li>",
"      Asymmetric distribution",
"     </li>",
"     <li>",
"      Distribution not in dependent areas",
"     </li>",
"     <li>",
"      Involvement of lips, larynx, and bowel",
"     </li>",
"     <li>",
"      Association of some forms of angioedema with anaphylaxis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angioedema may be due to allergic reactions (including drug reactions [eg, angiotensin converting enzyme inhibitors], insect bites, or food) and inherited or acquired deficiency of the C1 esterase inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"     \"An overview of angioedema: Pathogenesis and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Angioedema, when it involves the airway, is a medical emergency and requires emergent intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"     \"Basic airway management in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary angioedema due to deficiency in C1 inhibitor is quite rare. Affected patients with C1 inhibitor deficiency (hereditary angioedema [HAE]) commonly report a familial history of recurrent episodes of nonpainful, nonpruritic, and nonerythematous angioedema (without urticaria). An acquired form of this disorder also exists in which there is an autoantibody to the C1 inhibitor. This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=see_link\">",
"     \"Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome (NS) is one of the most common causes of generalized edema in childhood. The classic findings of this disorder include marked proteinuria, hypoalbuminemia, and hyperlipidemia, along with generalized edema.",
"   </p>",
"   <p>",
"    Edema formation in NS is a combination of the increased hydrostatic pressure due to primary renal sodium retention and decreased oncotic pressure due to hypoalbuminemia. The relative role for either process varies amongst individual patients. There also appears to be a role for increased capillary permeability mediated by a still unidentified factor or process. One proposed mechanism of sodium retention in NS is marked proteinuria causes conversion of plasminogen into plasmin within the tubular lumen, which leads to activation of epithelial sodium channel (ENaC) in the cortical collecting duct [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=see_link\">",
"     \"Pathophysiology and treatment of edema in patients with the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nephrotic syndrome with an onset prior to three months of age is known as congenital nephrotic syndrome, which is characterized by profound proteinuria and hypoalbuminemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The childhood nephrotic syndrome is associated with a number of glomerular lesions based on renal histology [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/16\">",
"     16",
"    </a>",
"    ]. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimal change disease is the most common cause of the nephrotic syndrome in children, accounting for 90 percent of cases in children younger than 10 years of age and more than 50 percent of cases in older children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other primary glomerular lesions include focal segmental glomerulosclerosis, mesangial proliferative glomerulonephritis, membranoproliferative glomerulonephritis, and membranous nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41717?source=see_link\">",
"       \"Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link\">",
"       \"Causes and diagnosis of membranous nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Secondary causes include systemic diseases such as systemic lupus erythematosus, Henoch Sch&ouml;nlein purpura (IgA vasculitis), and diabetes; and infections such as human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"       \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=see_link\">",
"       \"Overview of kidney disease in HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"       \"Renal disease associated with hepatitis B virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=see_link\">",
"       \"Renal disease associated with hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evaluation, diagnosis, and management of the child with nephrotic syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of minimal change disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=see_link\">",
"     \"Evaluation of proteinuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lymphatic dysfunction/obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysfunction and obstruction of the lymphatic vessels result in localized edema as the lymphatic load exceeds the transport capacity of the lymphatic system, resulting in accumulation of protein rich interstitial fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. A child with lymphedema may have either a primary defect of the lymphatics or a secondary (acquired) defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87257370\">",
"    <span class=\"h3\">",
"     Primary lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lymphedema can be divided into the following three different types based on the age of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lymphedema precox (77 to 94 percent) &ndash; Typically presents at onset of puberty",
"     </li>",
"     <li>",
"      Congenital lymphedema (6 to 12 percent) &ndash; Presents before two years of age",
"     </li>",
"     <li>",
"      Lymphedema tarda (11 percent) &ndash; Typically presents after 35 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798847249\">",
"    <span class=\"h4\">",
"     Lymphedema precox",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema precox is the most common form of primary lymphedema, accounting for 77 to 94 percent of all cases of primary lymphedema [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/22\">",
"     22",
"    </a>",
"    ]. Although it can occur between 2 and 36 years of age, it typically presents at the onset of puberty with unilateral edema, which in the majority of patients is limited to the foot and calf. Females are predominately affected with a reported 10-fold increase in prevalence in female versus male patients. The pathogenesis is unknown in the majority of cases, but it is speculated that estrogen may play a contributory role because the presentation of this condition most commonly occurs in girls at the onset of puberty.",
"   </p>",
"   <p>",
"    Although most cases are sporadic, 10 percent of cases of lymphedema precox are familial (referred to as Meige disease) with an autosomal dominant inheritance pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. Familial lymphedema precox has been associated with a double row of eyelashes (distichiasis) and is referred to as the lymphedema-distichiasis syndrome. A mutation in the FOXC2 gene (located at 16q24.3) has been described in families with lymphedema-distichiasis syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Mutation of FOXC2 results in agenesis of the lymphatic valves and enhanced recruitment of vascular mural cells to lymphatic capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, FOXC2 is highly expressed in venous valves, which could explain why approximately one-half of patients with lymphedema-distichiasis have venous insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798847282\">",
"    <span class=\"h4\">",
"     Congenital lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital lymphedema (presentation before two years of age) is due to a congenital",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inherited condition associated with pathologic development of the lymphatic vessels, which may include the following abnormalities",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced numbers of lymphatic collectors",
"     </li>",
"     <li>",
"      Lymphatic hypoplasia (decreased diameter of the lymphatic vessels)",
"     </li>",
"     <li>",
"      Lymphatic hyperplasia (increased diameter of lymphatic collectors)",
"     </li>",
"     <li>",
"      Lymphatic aplasia (absence of lymphatic system components)",
"     </li>",
"     <li>",
"      Lymph node fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following congenital conditions are associated with primary lymphedema in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary congenital lymphedema &ndash; Hereditary congenital lymphedema (primary congenital lymphedema, hereditary lymphedema type I, or Milroy&rsquo;s syndrome) is transmitted as an autosomal dominant trait [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/31\">",
"       31",
"      </a>",
"      ]. Affected individuals usually develop lymphedema in both lower extremities soon after birth, but it typically does not worsen over time. Most affected families carry a missense mutation in the gene encoding VEGFR-3 (expressed in the lymphatic endothelium), resulting in impaired lymphatic development [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/32-35\">",
"       32-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cholestasis-lymphedema syndrome &ndash; Cholestasis-lymphedema syndrome (Aagenaes syndrome) is an autosomal recessive disorder characterized by congenital lymphatic hypoplasia and recurrent cholestasis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/36\">",
"       36",
"      </a>",
"      ]. The lymphedema characteristically involves the legs of infants. Although the specific gene associated with this syndrome has yet to be identified, it is localized to chromosome 15q [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other conditions &ndash; Other conditions associated with congenital lymphedema include Noonan syndrome, Turner syndrome, and trisomy 18, 13, and 21. These conditions are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of short stature\", section on 'Noonan syndrome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H11#H11\">",
"       \"Congenital cytogenetic abnormalities\", section on 'Trisomy 18 syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H798847289\">",
"    <span class=\"h4\">",
"     Lymphedema tarda",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema tarda presents after 35 years of age. It also occurs more commonly in women and affects the lower extremities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Primary lymphedema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87258358\">",
"    <span class=\"h3\">",
"     Secondary lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphedema attributable to an acquired dysfunction of the lymphatic system may be caused by a wide range of conditions, including (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=see_link&amp;anchor=H213980183#H213980183\">",
"     \"Clinical manifestations and diagnosis of lymphedema\", section on 'Secondary lymphedema'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer and its treatment.",
"     </li>",
"     <li>",
"      Infection &ndash; Globally, lymphatic filariasis caused by the nematode",
"      <em>",
"       Wuscheria bancrofti",
"      </em>",
"      is the most common cause of acquired pediatric lymphedema [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=see_link\">",
"       \"Diagnosis, treatment, and prevention of lymphatic filariasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Autoimmune diseases &ndash; Lymphatic involvement can also occur in a variety of autoimmune diseases such as sarcoidosis, juvenile idiopathic arthritis, and Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1657/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"       \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Edema formation in children is a result of one or a combination of the following processes (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology of edema'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An alteration in capillary hemodynamics that favors the movement of fluid from the vascular space into the interstitium. These alterations include increased capillary hydrostatic pressure, decreased capillary oncotic pressure, and increased capillary permeability.",
"     </li>",
"     <li>",
"      A defective lymphatic system that fails to return interstitial fluid to the central venous system. Impaired lymphatic transport can be due to maldevelopment, injury, or obstruction of the lymphatic system. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Lymphatic dysfunction/obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The retention of dietary or intravenously administered sodium and water by the kidneys.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The etiology of edema in children can be classified by pathogenesis (",
"      <a class=\"graphic graphic_table graphicRef68106 \" href=\"UTD.htm?2/56/2957\">",
"       table 1",
"      </a>",
"      ). Understanding and identifying the underlying pathogenesis and cause of the edema can be helpful in the management of these patients. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7288?source=see_link\">",
"       \"Evaluation and management of edema in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lamb FS. Heart failure. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders, Philadelphia 1998. p.600.",
"    </li>",
"    <li>",
"     Gewitz MH, Woolf PK. Cardiac emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.717.",
"    </li>",
"    <li>",
"     Brouhard BH, et al. Acute postinfectious glomerulonephritis. In: Pediatric Kidney Disease, Edelmann CM (Ed), Little, Brown and Company, Boston 1992. p.1199.",
"    </li>",
"    <li>",
"     Blowey DL. Acute glomerulonephritis. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders, Philadelphia 1998. p.688.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/5\">",
"      Issa PY, Brihi ER, Janin Y, Slim MS. Superior vena cava syndrome in childhood: report of ten cases and review of the literature. Pediatrics 1983; 71:337.",
"     </a>",
"    </li>",
"    <li>",
"     Hagani A. Thrombophilia. In: Saunders Manual of Pediatric Practice, Finberg L (Ed), WB Saunders Company, Philadelphia 1998. p.431.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/7\">",
"      Chase HP, Kumar V, Caldwell RT, O'Brien D. Kwashiorkor in the United States. Pediatrics 1980; 66:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/8\">",
"      Martin PY, Gin&egrave;s P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339:533.",
"     </a>",
"    </li>",
"    <li>",
"     Brasitus TA. Protein-losing gastroenteropathy. In: Gastrointestinal Disease: Pathophysiology, Diagnosis, Management, Sleisenger JS (Ed), WB Saunders, Philadelphia 1993. p.1027.",
"    </li>",
"    <li>",
"     Thomas DW, et al. Protein-losing enteropathy. In: Principles and Practice of Pediatrics, Oski CD, Feigin RD, Warshaw JB (Eds), J.B. Lippincott Company, Philadelphia 1990. p.1722.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/11\">",
"      Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/12\">",
"      Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006; 175:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/13\">",
"      Davis RS, Vandewalker ML, Hutcheson PS, Slavin RG. Facial angioedema in children due to ladybug (Harmonia axyridis) contact: 2 case reports. Ann Allergy Asthma Immunol 2006; 97:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/14\">",
"      Svenningsen P, Bistrup C, Friis UG, et al. Plasmin in nephrotic urine activates the epithelial sodium channel. J Am Soc Nephrol 2009; 20:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/15\">",
"      Rondon-Berrios H. [New insights into the pathophysiology of oedema in nephrotic syndrome]. Nefrologia 2011; 31:148.",
"     </a>",
"    </li>",
"    <li>",
"     Valentini RP, Smoyer WE. Nephrotic Syndrome. In: Clinical Pediatric Nephrology, 2nd ed, Kher KK, Schnaper HW, Makker SP (Eds), Informa Healthcare, London 2007. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/17\">",
"      McAdams AJ, Valentini RP, Welch TR. The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change. Medicine (Baltimore) 1997; 76:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/18\">",
"      Menon S, Valentini RP. Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol 2010; 25:1419.",
"     </a>",
"    </li>",
"    <li>",
"     Olson JL, Schwartz MM. The Nephrotic Syndrome: Minimal change disease. Focal segmental glomerulosclerosis, and miscellaneous causes. In: Heptinstall's pathology of the kidney, Jennette JL, Schwartz MM, Silva FG (Eds), Lippincott-Raven, Philadelphia 1998. p.187.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/20\">",
"      Rockson SG. Lymphedema. Am J Med 2001; 110:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/21\">",
"      Lawenda BD, Mondry TE, Johnstone PA. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin 2009; 59:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/22\">",
"      Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. Vasc Med 1998; 3:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/23\">",
"      Lewis JM, Wald ER. Lymphedema praecox. J Pediatr 1984; 104:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/24\">",
"      Harel L, Amir J, Nussinovitch M, et al. Lymphedema praecox seen as isolated unilateral arm involvement: case report and review of the literature. J Pediatr 1997; 130:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/25\">",
"      Wheeler ES, Chan V, Wassman R, et al. Familial lymphedema praecox: Meige's disease. Plast Reconstr Surg 1981; 67:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/26\">",
"      Connell F, Brice G, Mortimer P. Phenotypic characterization of primary lymphedema. Ann N Y Acad Sci 2008; 1131:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/27\">",
"      Finegold DN, Kimak MA, Lawrence EC, et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet 2001; 10:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/28\">",
"      Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 2000; 67:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/29\">",
"      Petrova TV, Karpanen T, Norrm&eacute;n C, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004; 10:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/30\">",
"      Mellor RH, Brice G, Stanton AW, et al. Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb. Circulation 2007; 115:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/31\">",
"      Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema: a comprehensive review. Ann Plast Surg 2007; 59:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/32\">",
"      Evans AL, Brice G, Sotirova V, et al. Mapping of primary congenital lymphedema to the 5q35.3 region. Am J Hum Genet 1999; 64:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/33\">",
"      Ferrell RE, Levinson KL, Esman JH, et al. Hereditary lymphedema: evidence for linkage and genetic heterogeneity. Hum Mol Genet 1998; 7:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/34\">",
"      Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/35\">",
"      M&auml;kinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/36\">",
"      Bull LN, Roche E, Song EJ, et al. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am J Hum Genet 2000; 67:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/37\">",
"      Witt C, Ottesen EA. Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001; 6:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/38\">",
"      Athreya BH, Ostrov BE, Eichenfield AH, Goldsmith DP. Lymphedema associated with juvenile rheumatoid arthritis. J Rheumatol 1989; 16:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1657/abstract/39\">",
"      Murphy MJ, Kogan B, Carlson JA. Granulomatous lymphangitis of the scrotum and penis. Report of a case and review of the literature of genital swelling with sarcoidal granulomatous inflammation. J Cutan Pathol 2001; 28:419.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6096 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1657=[""].join("\n");
var outline_f1_39_1657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology of edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Altered capillary hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Impaired lymphatic transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Renal salt and water retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Increased hydrostatic pressure from sodium and water retention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acute glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Increased capillary hydrostatic pressure from obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Venous obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Decreased capillary oncotic pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Protein malnutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Protein losing enteropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Increased capillary permeability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Angioedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lymphatic dysfunction/obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87257370\">",
"      - Primary lymphedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H798847249\">",
"      Lymphedema precox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H798847282\">",
"      Congenital lymphedema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H798847289\">",
"      Lymphedema tarda",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87258358\">",
"      - Secondary lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6096|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/10/14507\" title=\"figure 1\">",
"      Capillary hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/56/2957\" title=\"table 1\">",
"      Causes edema childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/33/42523\" title=\"table 2\">",
"      Causes of glomerulonephritis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=related_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24519?source=related_link\">",
"      Approach to neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/49/40729?source=related_link\">",
"      Clinical manifestations and diagnosis of Henoch-Sch&ouml;nlein purpura (IgA vasculitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/52/1866?source=related_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36377?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/56/15241?source=related_link\">",
"      Diagnosis, treatment, and prevention of lymphatic filariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9466?source=related_link\">",
"      Etiology and diagnosis of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34601?source=related_link\">",
"      Etiology, clinical features, and diagnosis of minimal change disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/7/7288?source=related_link\">",
"      Evaluation and management of edema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11238?source=related_link\">",
"      Evaluation of a child with glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26262?source=related_link\">",
"      Evaluation of proteinuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19272?source=related_link\">",
"      Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/426?source=related_link\">",
"      Idiopathic systemic capillary leak syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41717?source=related_link\">",
"      Minimal change variants: Mesangial proliferation; IgM nephropathy; C1q nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4168?source=related_link\">",
"      Overview of kidney disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4409?source=related_link\">",
"      Pathogenesis and diagnosis of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/16/14600?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/34/36393?source=related_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36008?source=related_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37353?source=related_link\">",
"      Renal disease associated with hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_39_1658="Complications of total hip arthroplasty";
var content_f1_39_1658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of total hip arthroplasty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Greg A Erens, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Thomas S Thornhill, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Jeffrey N Katz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/39/1658/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/39/1658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most complications in total hip arthroplasty are infrequent and can be prevented or treated readily if anticipated and recognized. Complications associated with any major surgical procedure, including those related to anesthesia, comorbid medical conditions, medications, and allergic reactions may also occur.",
"   </p>",
"   <p>",
"    Potential complications known to occur during or following total hip arthroplasty will be reviewed here. The complications can be categorized as intraoperative or postoperative. The preoperative assessment, the alternatives to total hip arthroplasty, and an overview of the surgical procedure itself are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"     \"Total hip arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of fracture during total hip arthroplasty ranges from 0.1 to 1 percent for cemented components and from 3 to 18 percent for uncemented components [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/1\">",
"     1",
"    </a>",
"    ]. Most intraoperative fractures occur on the femoral side during stem insertion. Minor fractures may be left alone or treated with wires or cables. More extensive fractures may require more complex solutions including revision of components, bone grafting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supplementary hardware (eg, plates and screws). Factors that increase the risk of fracture during primary arthroplasty include female sex, osteopenia, inflammatory arthropathies, and cementless stem fixation. The use of longer stem cementless implants during revision surgery is an additional risk factor for fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of nerve injury in primary total hip arthroplasty ranges from 0 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/3\">",
"     3",
"    </a>",
"    ]. Injury to the sciatic nerve is most common, but the femoral, obturator, and superior gluteal nerves may also be injured. The peroneal division of the sciatic nerve is more susceptible to injury than the tibial division.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for nerve injury include previous surgery, developmental dysplasia of the hip, lengthening of the extremity, obesity, and female sex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of nerve injury is unknown in almost 50 percent of cases. Known causes include compression due to hematoma or hardware, direct trauma (eg, retractor), transection, excessive lengthening of the extremity, ischemia, thermal injury secondary to cement, and dislocation. The wound should be inspected for large hematoma, and radiographs should be inspected for evidence of excessive lengthening, dislocation, and hardware position (eg, screws). The use of magnetic resonance imaging of the pelvis and lumbosacral plexus is helpful in identifying potential sources of neural compromise, including hematoma in the gluteal space and extradural impingement [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment depends on the cause of injury. If discovered immediately postoperatively, flexion of the hip and knee will reduce tension on the sciatic and femoral nerves.",
"   </p>",
"   <p>",
"    Surgical exploration is indicated for suspected nerve palsies caused by large hematoma, excessive limb lengthening, and nerve laceration. For other unidentifiable causes, observation is appropriate. An ankle-foot orthosis should be utilized during rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis for recovery is variable and is directly correlated with the degree of nerve injury. Mixed sensory and motor losses have the poorest prognosis. Isolated peroneal injury has a better prognosis than complete sciatic palsy. Complete recovery occurs in approximately 41 percent, and another 44 percent have only a mild deficit. Approximately 15 percent have a poor outcome characterized by weakness that limits ambulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    persistent dysesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vascular injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular injury, while quite rare in total hip arthroplasty, can be a devastating complication. The incidence of vascular injury ranges from 0.2 to 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/6\">",
"     6",
"    </a>",
"    ]. Major vessels that may be injured include the iliac and femoral vessels, profunda femoris artery, obturator artery, and superior gluteal artery. Intraoperative injuries are often lacerations or punctures of vessels; injuries that may be recognized postoperatively are arteriovenous fistulas, arterial thromboses, and pseudoaneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of vascular injury include the use of retractors, osteotomes, or a scalpel near vascular structures; cerclage wiring; excessive dissection or traction on tissues; and acetabular screw placement. An acetabular quadrant system described by Wasielewski et al [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/8\">",
"     8",
"    </a>",
"    ] warns against placement of screws in the anterosuperior quadrant (threatening the external iliac artery and vein) and anteroinferior quadrant (threatening the iliac vessels and the obturator nerve).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of bleeding intraoperatively must be performed. In some cases, simple measures such as ligation or electrocautery may be effective. However, more severe vessel injury may require formal exposure and a vascular consult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cement-related hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of acute hypotension associated with the use of polymethylmethacrylate (PMMA) cement is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/1\">",
"     1",
"    </a>",
"    ]. A significant drop in systolic blood pressure (20 mm Hg or more) may occur during the insertion of a cemented femoral component. Use of a long stem femoral component is a significant risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential mechanisms have been proposed to account for this phenomenon. The main cause is believed to be embolization of fat and marrow debris. Other contributing causes may be cement monomer toxicity, anaphylatoxin release, and prostaglandin release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prevention and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of this condition includes pulse lavage of the femoral canal, slow introduction of the stem, a vent hole in the bone for long stem component insertion, and minimal pressurization of cement. Patients suspected of having this condition are typically managed with use of 100 percent inhaled O",
"    <sub>",
"     2",
"    </sub>",
"    , adequate volume replacement, and use of invasive monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Thromboembolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolic disease is the complication that presents the highest risk of perioperative mortality following total hip arthroplasty. Those who have had such surgery are in the highest risk group of postsurgical patients (",
"    <a class=\"graphic graphic_table graphicRef58607 \" href=\"UTD.htm?38/34/39468\">",
"     table 1",
"    </a>",
"    ). Stasis due to torsion of the lower limb during surgery, as well as intimal injury, has been implicated in the etiology of thromboembolic events following hip arthroplasty, but the precise etiology remains uncertain. The incidence of lower extremity deep vein thrombosis (DVT) has been reported as high as 70 percent and as low as 8 percent. Without thromboprophylaxis, perioperative mortality from pulmonary embolus (PE) occurs in 2 to 3 percent. With thromboprophylaxis, there is a 0.1 percent rate of post-discharge fatal PE at 90 days postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/10\">",
"     10",
"    </a>",
"    ]. While some form of prophylaxis is warranted, the challenge for the orthopaedic surgeon is to balance the risk of a major thromboembolic event with the risk of bleeding due to the use of an anticoagulant agent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients receiving thromboprophylaxis, following total or partial hip arthroplasty and prior to hospital discharge, the rates of inpatient venous thromboembolism (VTE) were estimated in a meta-analysis. This analysis involved 21,369 patients in 27 randomized trials and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/12\">",
"     12",
"    </a>",
"    ]. Symptomatic postoperative VTE before hospital discharge occurred in 0.53 percent (95% CI 0.35-0.7 percent), symptomatic DVT occurred in 0.26 percent (95% CI 0.14-0.37 percent), and PE occurred in 0.14 percent (95% CI 0.07-0.21 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention is the key to minimizing the risk of thromboembolism following total hip arthroplasty. A plethora of medications and therapeutic modalities have been utilized for prophylaxis. Prophylactic regimens and recommendations for preventing postoperative venous thromboembolic disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to diagnosis and treatment of venous thromboembolic disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of infection in primary total hip arthroplasty varies from 0.4 percent to 1.5 percent. Prosthetic joint infection can be a devastating and costly complication following total hip arthroplasty. The pathogenesis, clinical manifestations, treatment, and prevention of prosthetic joint infections are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link\">",
"     \"Prevention of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocation of a prosthetic hip can be a terrifying problem for the patient and a frustrating one for the surgeon. The overall incidence of dislocation in primary total hip arthroplasty ranges from 0 to 2 percent. The majority of dislocations occur posteriorly, typically with flexion, adduction, and internal rotation of the limb. Anterior dislocations are less frequent and typically occur with extension, adduction, and external rotation of the limb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the dislocation rate following a posterolateral approach was greater than that following a modified lateral approach. A posterolateral approach utilizing a posterior capsular repair can reduce the dislocation rate to less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This compares with a rate of less than 1 percent using the modified lateral approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Besides surgical approach, other factors that influence dislocation include implant design, implant orientation and alignment, and status of the soft tissues (particularly the abductors). In addition, patient factors that are associated with increased risk of dislocation include female sex, advanced age, and history of previous hip procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is dependent on identification of the cause and direction of dislocation. Most first time dislocations can be managed with simple closed reduction. These early (&lt;3 months postoperative) dislocations can be successfully treated without recurrence in 60 to 70 percent of instances [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/16\">",
"     16",
"    </a>",
"    ]. For repeat dislocation, addition of a brace may be considered. Unfortunately, the data supporting brace use are not encouraging, with roughly 60 percent of patients continuing to dislocate despite brace use [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/17\">",
"     17",
"    </a>",
"    ]. For dislocation as the result of failed implants, implant malalignment, excessive soft tissue laxity, or recurrent instability, surgical treatment is often necessary. A success rate of 80 percent can be expected for reoperations in which the specific cause of the dislocation has been well-defined. The success rate drops to approximately 50 percent for reoperations in which the cause of the dislocation is nonspecific or ill-defined [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/16\">",
"     16",
"    </a>",
"    ]. The highest success rate has been with constrained acetabular components, although late mechanical failure and loosening have been observed in this group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Osteolysis and wear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteolysis is a process in which bone is resorbed as a biologic response to particulate debris. Periprosthetic osteolysis has emerged as the most common long-term complication seen in total hip arthroplasty and the most frequent reason for implant failure. The incidence of osteolysis varies widely and is dependent on many factors including implant design and materials, type of fixation (cemented or uncemented), and surgical technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periprosthetic osteolysis is typically asymptomatic unless it progresses to aseptic loosening. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Aseptic loosening'",
"    </a>",
"    below.) When osteolysis is accompanied by pain, it generally reflects loss of implant fixation or a pathologic fracture. Pain may also be the result of a reactive synovitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common factor in cases of osteolysis is wear and the resultant production of particulate debris, including polyethylene, metal, ceramic, and acrylic bone cement (typically in the micron or submicron range). A higher particle load is associated with a greater osteolytic response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/19\">",
"     19",
"    </a>",
"    ]. The process begins as wear particles from the hip implant are phagocytosed by macrophages that become activated. These activated macrophages release osteolytic factors and stimulate osteoclasts to dissolve surrounding bone [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteolysis is accompanied by expression on macrophages of a disintegrin and metalloproteinase (ADAM) family proteins, including ADAM8 (CD156), ADAM9, and ADAM12 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. These molecules, which have enzymatic and integrin-like functions, may play a role in matrix degradation and stimulation of formation of multinucleated foreign-body giant cells and osteoclasts.",
"   </p>",
"   <p>",
"    Fibroblasts present in tissue at the interface between the prosthesis and bone may also play a role in promoting osteolysis. These cells produce proteins that can contribute to bone resorption including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Receptor activator of nuclear factor kappa B ligand (RANK ligand or RANKL) is a differentiation factor for osteoclast precursors and promotes development of osteoclasts. Ordinarily RANKL is thought to be important in normal bone remodeling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link&amp;anchor=H1206113#H1206113\">",
"       \"Normal skeletal development and regulation of bone formation and resorption\", section on 'Remodeling'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cathepsin K, a proteolytic enzyme that is active at low pH and which can degrade type I collagen found in bone matrix",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the bone surrounding the implants is dissolved, micromotion may occur. This, in turn, may produce additional wear debris. Subsequently, loss of implant fixation, pathologic fracture, or impending pathologic fracture can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Radiographic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographically, osteolysis appears as endosteal, intracortical, or non-linear cancellous bone destruction. Lesions can become quite large and expansile, especially on the acetabular side. Bone loss is often significant by the time osteolysis appears on plain radiographs. Magnetic resonance imaging (MRI) or computed tomography (CT) scanning with metal artifact suppression can provide better visualization of osteolytic defects than plain radiographs and are useful in determining the size of lesions. MRI may be more sensitive than CT scanning according to some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;To decrease wear and subsequent osteolysis, much attention has been directed toward elimination of possible sources of wear and particulate debris. The most common source of such debris is polyethylene from the articulation between the femoral head and acetabular liner. Highly crosslinked polyethylene with improved resistance to wear has been developed as a possible solution. Mid-term results with highly crosslinked polyethylene are promising, but longer clinical follow-up is necessary. A randomized trial comparing conventional polyethylene with highly cross-linked polyethylene demonstrated significantly lower wear rates with use of the highly cross-linked product at a mean of 6.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, alternate bearing surfaces such as ceramic-on-polyethylene, ceramic-on-ceramic, and metal-on-metal have also been utilized in an attempt to slow or halt the generation of wear debris [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/27\">",
"     27",
"    </a>",
"    ]. Concerns related to metal-on-metal implants are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link&amp;anchor=H30#H30\">",
"     \"Total hip arthroplasty\", section on 'Bearing surface'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other approaches to preventing osteolysis are also being explored. As an example, the use of oral bisphosphonates to inhibit osteoclast activity, and thus to prevent osteolysis secondary to wear debris, has been studied using several strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. A population based study of 41,995 patients undergoing initial hip or knee joint arthroplasty showed a reduced rate of subsequent revision arthroplasty in patients who had received prior oral bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/30\">",
"     30",
"    </a>",
"    ]. The study examined the 1912 patients in the population cohort who underwent initial joint arthroplasty and had used oral bisphosphonates for at least six months at some time prior to their surgery. There was a significantly lower rate of revision at five years, compared with patients who did not use bisphosphonates (0.93 percent, 95% CI 0.52-1.68 percent, versus 1.96 percent, 95% CI 1.80-2.14 percent). The results for hip and knee arthroplasty patients respectively trended in a fashion similar to the results for the pooled analysis, but the results in the two subgroups did not achieve statistical significance. Thus, confirmation in other cohorts and randomized trials with adequate follow-up will be needed to establish the role of bisphosphonates in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14353540\">",
"    <span class=\"h4\">",
"     Metal-on-metal bearing surfaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant concerns have been raised regarding the use of metal-on-metal (MOM) as a bearing surface. There are two types of MOM bearing that should be distinguished: MOM hip replacements and MOM hip resurfacing.",
"   </p>",
"   <p>",
"    Several issues have been identified with MOM hip replacements with respect to bearing wear and adverse reactions to metal debris, and design-related variables associated with higher implant failure have been recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/31\">",
"     31",
"    </a>",
"    ]. These include implants with a reduced articular surface geometry that may predispose to accelerated wear [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, implants placed in extremes of abduction or anteversion also appear at risk for early failure due to the consequence of bearing wear [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/33\">",
"     33",
"    </a>",
"    ]. The clinical sequela of MOM bearing wear and the biologic response to it are varied but can range from moderate pain due to a local inflammatory reaction to widespread soft tissue destruction as a result of an extensive immunologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management recommendations by regulatory agencies differ between countries, and devices available in one country are not necessarily available in another. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The US Food and Drug Administration (FDA) has issued a",
"      <a class=\"external\" href=\"file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm335775.htm\">",
"       Safety Communication",
"      </a>",
"      regarding the metal-on-metal implants, along with additional detailed information and management recommendations (",
"      <a class=\"external\" href=\"file://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/MetalonMetalHipImplants/default.htm\">",
"       FDA Medical Devices Metal-on-Metal Implants",
"      </a>",
"      ), which were updated January 17, 2013 [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. For symptomatic patients, the FDA recommends clinical evaluation at least every six months, and that imaging and metal ion testing may be considered. In asymptomatic patients, clinical evaluation is recommended typically at least once every one to two years, and imaging and metal ion testing are not thought to be necessary if the hip is functioning properly.",
"     </li>",
"     <li>",
"      The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom issued a medical alert, updated June 25, 2012 (",
"      <a class=\"external\" href=\"file://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON155761\">",
"       MHRA Medical Device Alert",
"      </a>",
"      ), detailing their management recommendations for patients with these implants with regard to frequency of follow-up, imaging, measurement of blood metal ion levels, and indications for considering surgical revision [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/37\">",
"       37",
"      </a>",
"      ]. Imaging with metal artifact reduction sequence (MARS) MRI or ultrasound and blood metal ion testing are recommended by the MHRA for all symptomatic patients and for several categories of asymptomatic patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatments available for osteolysis are surgical. The indications for surgery are dependent on many factors, but most orthopedic surgeons agree that a symptomatic patient with a pathologic fracture, an impending pathologic fracture, or extensive osteolysis with a loose component requires surgical intervention. Optimal management of the asymptomatic patient with significant osteolysis is uncertain. Exchange of the acetabular liner with removal of granulomatous tissue has the potential to decrease wear and slow the progression of osteolysis without subsequent component loosening [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Aseptic loosening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major long-term problem associated with total hip arthroplasty today is loss of fixation (aseptic loosening). This is most often caused by wear of the prosthetic components (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Osteolysis and wear'",
"    </a>",
"    above). The risk of aseptic loosening leading to revision THA is about 1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/41\">",
"     41",
"    </a>",
"    ]. Other etiologies include poor initial stability of the implant, poor implant design, patient factors (eg, age, weight, activity level, underlying diagnosis), and failure of fixation. In cementless implants, poor host response and lack of biologic integration may be causes. In cemented implants, poor cement technique or cement",
"    <span class=\"nowrap\">",
"     fatigue/fracture",
"    </span>",
"    may be a cause. Overall, the incidence of aseptic loosening is highly variable. Improvements in bearing surface wear characteristics, implant design, surgical technique, and patient selection have all led to a decreasing incidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although periprosthetic osteolysis may be asymptomatic, aseptic loosening often is associated with pain. Loosening of the femoral component typically causes deep-seated aching in the proximal and medial aspect of the thigh that is worse with weight bearing and better with rest or unloading the hip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Radiographic appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic appearance is the same as for asymptomatic osteolysis. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Osteolysis and wear'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aseptic loosening must be differentiated from prosthetic joint infection. Various tests have been used to try to differentiate these two disorders. The most definitive is joint aspiration and culture. In some cases, bone biopsy is necessary to clarify the etiology. Intraoperative cultures at the time of revision arthroplasty may also be indicated in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"     \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Periprosthetic fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;A periprosthetic fracture is a fracture that occurs in proximity to an implant. This is a rare postoperative complication with an incidence of less than 1 percent following primary total hip arthroplasty. Periprosthetic fractures occur most often on the femoral side at sites of osteolytic lesions or areas where stress risers exist (eg, cortical perforation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of classification schemes have been described, but the Vancouver classification system is often utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/42\">",
"     42",
"    </a>",
"    ]. Fractures are divided into type A, B, or C. Type A fractures are trochanteric in location. Type B fractures are located about the stem or tip of stem. These are subclassified into B1 (a well-fixed stem), B2 (a loose stem), and B3 (marked osseous deficiency or destruction). Type C fractures are well distal to the tip of the stem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for periprosthetic fractures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonoperative management (eg, protected weight-bearing, traction, or casting)",
"     </li>",
"     <li>",
"      Revision arthroplasty",
"     </li>",
"     <li>",
"      Internal fixation (using plates, screws, wires, cables",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cortical strut grafts)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the inherent variability of these fractures, no single approach can be applied to all cases. Management of periprosthetic fractures must be individualized and must take into consideration many factors including age and physical demands of the patient, limb alignment, fracture location, fracture pattern, bone quality, location of any bone defects, type of implant fixation (cemented versus cementless), and stability of the implant.",
"   </p>",
"   <p>",
"    Nonoperative treatment is considered for stable fractures around well-fixed and functional implants (eg, nondisplaced trochanteric fracture or a longitudinal split in the proximal femur recognized incidentally on postoperative radiographs).",
"   </p>",
"   <p>",
"    Operative treatment is indicated for unstable fractures and fractures associated with loose or otherwise failed prostheses. The surgical treatment of choice is usually determined by whether the stem is loose or well-fixed. If the stem is loose, revision arthroplasty with a long-stem implant is the recommended treatment. Internal fixation may be indicated for unstable fractures with a well-fixed stem [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Implant failure or fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of femoral component fractures has been estimated at 0.27 percent in a retrospective survey conducted by the American Association of Hip and Knee Surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/44\">",
"     44",
"    </a>",
"    ]. Stems utilizing modern metallurgy and manufacturing techniques have nearly eliminated stem breakage as a complication. Forged femoral components with decreased grain size, microporosity, and inclusions have greatly improved fatigue strength as compared with prior cast or annealed implants [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Implant breakage is typically the result of deformation and fatigue fracture caused by repetitive loading (usually over the course of years). An incomplete fatigue fracture can progress to catastrophic failure with continued loading. Early femoral stem designs that utilized stainless steel with inadequate cross-sectional area and high offset were particularly vulnerable. In addition to inadequate fatigue strength of the metal, other factors that predispose to implant fracture are increased patient weight, high patient activity level, and poor implant fixation and stability [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Leg length discrepancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leg length discrepancy is the number one reason for lawsuits against orthopedic surgeons performing total hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/48\">",
"     48",
"    </a>",
"    ]. The problem is concerning for both patient and surgeon. If a leg length discrepancy occurs, the patient may require a shoe lift to equalize the limb lengths. With significant inequality, a limp, low back pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the need for a cane are more common.",
"   </p>",
"   <p>",
"    During total hip arthroplasty, every attempt is made to equalize leg lengths",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restore normal leg length. Numerous factors affect perceived postoperative leg length, and true leg length should be differentiated from apparent leg length. There is no universal consensus on what constitutes a significant inequality [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/49\">",
"     49",
"    </a>",
"    ]. Some surgeons define a significant difference as 2 cm or more. Others define a significant difference as one that adversely affects patient function. Regardless of which definition is used, special attention to this issue needs to be made preoperatively, intraoperatively, and postoperatively.",
"   </p>",
"   <p>",
"    Preoperatively, leg lengths should be measured and recorded. Evaluation of outside factors affecting leg length (eg, scoliosis, pelvic obliquity, adduction contracture) should also be noted. Discussion with the patient regarding perceived leg length inequality is also important. It is imperative to discuss the risk of leg length inequality as a routine part of the preoperative informed consent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link&amp;anchor=H11#H11\">",
"     \"Total hip arthroplasty\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraoperatively, there are many techniques for leg length determination. These range from special devices that measure from a fixed point on the pelvis to a simple comparison of intraoperative knee and heel positions. Intraoperative radiographs may also be very useful. Some method must be used, and redundancy is desirable. Sometimes surgeons will need to lengthen a leg because the soft tissues around the hip (mainly the abductors) are too lax. If these tissues are too lax, the hip is more likely to dislocate. Ultimately, hip stability is more important than leg length discrepancy. Most surgeons would accept a small leg length inequality in exchange for a hip that is more stable and less likely to dislocate.",
"   </p>",
"   <p>",
"    Postoperatively, leg lengths should again be evaluated and measured. There is wide variability in patient perception of postoperative leg length. Some patients may perceive a significant discrepancy when true leg lengths are in fact equal. This apparent (or functional) leg length discrepancy may be due to hip muscle weakness in the early postoperative period and often resolves within a few months. These patients should be counseled regarding this, and physical therapy should emphasize progressive strengthening and stretching to help the patient return to a normal gait pattern. Some patients with a true discrepancy may require a shoe lift for the short limb, while others will not even notice an inequality that exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Heterotopic ossification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterotopic ossification (HO) is a process by which the soft tissues around the hip become ossified. HO that occurs in muscle is also known as myositis ossificans. Following total hip arthroplasty, HO typically occurs around the femoral neck and adjacent to the greater trochanter. HO occurs when primitive mesenchymal cells in the surrounding soft tissues are transformed into osteoblastic tissue. This tissue then forms mature lamellar bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of HO following total hip arthroplasty varies widely and may reach up to 90 percent when evaluated in high risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Risk factors for HO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact trigger for HO following total hip arthroplasty is unknown, but risk factors have been identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HO is twice as common in males as compared with females.",
"     </li>",
"     <li>",
"      Patients at high risk for developing HO after total hip arthroplasty include men with bilateral hypertrophic osteoarthritis, patients with a history of HO in either hip, and patients with posttraumatic arthritis characterized by hypertrophic osteophytosis.",
"     </li>",
"     <li>",
"      Patients at moderate risk include those with ankylosing spondylitis, diffuse idiopathic skeletal hyperostosis (DISH), Paget disease, or unilateral hypertrophic osteoarthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other risk factors include females over the age of 65 at the time of surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/53\">",
"       53",
"      </a>",
"      ] and a lateral surgical approach to the hip [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/54\">",
"       54",
"      </a>",
"      ]. Although one study by Maloney et al [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/55\">",
"       55",
"      </a>",
"      ] found that the incidence of HO was higher with cementless femoral components, more recent studies have shown that type of fixation (cemented or cementless) does not affect the incidence of HO [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/56-58\">",
"       56-58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip stiffness is the most common complaint. Pain is rarely a problem. Many patients with radiographically low-grade HO are asymptomatic. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with severe HO may have signs of inflammation including fever, erythema, swelling, warmth, and tenderness. Such findings are also suggestive of wound or prosthetic joint infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of severe HO has been correlated with a sedimentation rate greater than 35",
"    <span class=\"nowrap\">",
"     mm/hr",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/59\">",
"     59",
"    </a>",
"    ] and a serum alkaline phosphatase greater than 250 international",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/60\">",
"     60",
"    </a>",
"    ] at 12 weeks postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;HO is typically evaluated radiographically. The most widely accepted classification system includes four grades based on an AP radiograph of the pelvis and hip [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I represents islands of bone within soft tissues about the hip.",
"     </li>",
"     <li>",
"      Grade II includes bone spurs adjacent to the pelvis or proximal end of the femur leaving at least 1 cm between opposing bone surfaces.",
"     </li>",
"     <li>",
"      Grade III represents bone spurs adjacent to the pelvis or proximal end of the femur leaving less than 1 cm between opposing bone surfaces.",
"     </li>",
"     <li>",
"      Grade IV represents radiographic ankylosis of the hip.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings of ossification may be visible on plain radiographs within three to four weeks postoperatively. Maturation of the HO may take up to one or two years. Bone scanning typically shows increased uptake in the soft tissues adjacent to the hip, but these findings are not specific for HO.",
"   </p>",
"   <p>",
"    The maturation process can be monitored by serial radiographs or bone scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Prophylaxis for HO",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in effective prophylaxis is to identify patients who are at high risk for HO preoperatively. (See",
"    <a class=\"local\" href=\"#H40\">",
"     'Risk factors for HO'",
"    </a>",
"    above.) Routine use of prophylaxis is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/62\">",
"     62",
"    </a>",
"    ]. Currently, nonsteroidal antiinflammatory drugs (NSAIDs) and external beam radiation have been used most successfully in preventing HO. Prophylactic measures against HO after total hip arthroplasty should be administered before the fifth postoperative day, optimally within 24 to 48 hours.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of NSAIDs &mdash; A meta-analysis of prevention trials concluded that NSAIDs are effective in reducing the risk of post-operative HO [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/63\">",
"       63",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       Indomethacin",
"      </a>",
"      is the most commonly used NSAID for HO prophylaxis, although other NSAIDs have demonstrated some effectiveness.",
"      <br/>",
"      <br/>",
"      Limited data are available that address the relative effectiveness of selective COX-2 inhibitors in HO prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. The somewhat selective COX-2 inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"       meloxicam",
"      </a>",
"      was less effective than indomethacin [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/64\">",
"       64",
"      </a>",
"      ], while the more selective COX-2 inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      , was more effective than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/65\">",
"       65",
"      </a>",
"      ] and was similar to indomethacin in preventing postoperative HO with fewer discontinuations due to adverse effects in another [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/66\">",
"       66",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The recommended dose of indomethacin is 75 to 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and should be continued for 7 to 14 days postoperatively. Bleeding complications are more frequent in patients receiving NSAIDs in conjunction with anticoagulation for thromboembolic prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. Careful monitoring should be implemented [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/67\">",
"       67",
"      </a>",
"      ]. Prophylactic use of a proton-pump inhibitor may reduce the risk of NSAID-induced gastroduodenal damage and subsequent gastrointestinal bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=see_link\">",
"       \"NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      External beam radiation &mdash; External beam radiation has also demonstrated efficacy in prevention of HO after total hip arthroplasty. A year 2004 meta-analysis of seven randomized studies that compared radiation with NSAIDs concluded that radiotherapy is more effective, but the absolute difference in the rates of clinically significant HO are quite small, on the order of 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/69\">",
"       69",
"      </a>",
"      ]. A single dose regimen of 700 or 800 centigray is recommended. Radiation may be administered preoperatively (within 24 hours) or postoperatively (within 72 hours) [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/70-73\">",
"       70-73",
"      </a>",
"      ]. Currently, there is no clinical evidence supporting malignant transformation following this type of single dose regimen. If cementless prosthetic components are used, the ingrowth areas may be shielded from the radiation beam, though observational data suggest that shielding the prosthesis is associated with an increased incidence of HO compared with unshielded radiation that includes the acetabular and proximal femoral regions [",
"      <a class=\"abstract\" href=\"UTD.htm?1/39/1658/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"       \"Patient information: Hip replacement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=see_link\">",
"       \"Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H239249938\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The complications of total hip arthroplasty can be categorized as intraoperative or postoperative. Most are infrequent and can be prevented or treated readily if anticipated and recognized. Additionally, complications associated with any major surgical procedure may also occur. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major potential intraoperative complications include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fracture &mdash; Most intraoperative fractures are minor and occur during insertion of the femoral component. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nerve injury &mdash; Injury to the sciatic nerve is the most common; surgical treatment is usually reserved for suspected nerve palsies due to large hematomas, excessive limb lengthening, or known nerve laceration. The prognosis is variable. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nerve injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular injury &mdash; Vascular injury is very rare but may affect major vessels. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Vascular injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cement-related hypotension &mdash; The incidence of acute hypotension associated with the use of polymethylmethacrylate cement is less than 5 percent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cement-related hypotension'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major potential postoperative complications include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thromboembolic disease &mdash; Thromboembolic disease is the complication that presents the highest risk of perioperative mortality following total hip arthroplasty. Prevention is the key to minimizing the risk. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Thromboembolic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection &mdash; Infection occurs in approximately 1 percent of patients following primary total hip arthroplasty; prevention is critical. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dislocation &mdash; The risk of hip dislocation, which may occur in up to 2 percent of patients, is affected by a number of factors. The majority occur posteriorly. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteolysis and wear &mdash; Osteolysis is a process in which bone is resorbed as a biologic response to particulate debris. Periprosthetic osteolysis is the most common long-term complication seen in total hip arthroplasty and the most significant reason for implant failure. Periprosthetic osteolysis is typically asymptomatic unless it progresses to aseptic loosening. The treatments are surgical. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Osteolysis and wear'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aseptic loosening &mdash; The major long-term problem associated with total hip arthroplasty is loss of fixation (aseptic loosening). This is most often caused by wear of the prosthetic components, but other etiologies include poor initial stability of the implant, poor implant design, patient factors, and failure of fixation. Aseptic loosening is often associated with pain and must be differentiated from prosthetic joint infection. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Aseptic loosening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Periprosthetic fracture &mdash; Periprosthetic fracture, which occurs in proximity to an implant, is rare. Nonoperative treatment is considered for stable fractures around well-fixed and functional implants, while operative treatment is indicated for unstable fractures and fractures associated with loose or otherwise failed prostheses. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Periprosthetic fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Implant",
"      <span class=\"nowrap\">",
"       failure/fracture",
"      </span>",
"      &mdash; Implant breakage is typically the result of deformation and fatigue fracture caused by repetitive loading, usually over the course of years, but stems utilizing modern metallurgy and manufacturing techniques have nearly eliminated stem breakage as a complication. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Implant failure or fracture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leg length discrepancy &mdash; Leg length discrepancies may require a shoe lift to equalize limb length. With significant inequality, a limp, low back pain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the need for a cane are more common. There is no universal consensus on how to define a significant inequality. Attention should be given to this issue preoperatively, intraoperatively, and postoperatively. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Leg length discrepancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heterotopic ossification &mdash; Heterotopic ossification (HO) is a process by which the soft tissues around the hip become ossified. HO that occurs in muscle is also known as myositis ossificans. Following total hip arthroplasty, HO typically occurs around the femoral neck and adjacent to the greater trochanter. The incidence varies widely; multiple different factors may predict increased risk. Hip stiffness is the most common symptom. Nonsteroidal antiinflammatory drugs (NSAIDs) and external beam radiation have been used most successfully in preventing HO. (See",
"      <a class=\"local\" href=\"#H38\">",
"       'Heterotopic ossification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466589287\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Douglas E Padgett, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/1\">",
"      Saleh KJ, Kassim R, Yoon P, Vorlicky LN. Complications of total hip arthroplasty. Am J Orthop (Belle Mead NJ) 2002; 31:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/2\">",
"      Davidson D, Pike J, Garbuz D, et al. Intraoperative periprosthetic fractures during total hip arthroplasty. Evaluation and management. J Bone Joint Surg Am 2008; 90:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/3\">",
"      DeHart MM, Riley LH Jr. Nerve injuries in total hip arthroplasty. J Am Acad Orthop Surg 1999; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/4\">",
"      Beksa&ccedil; BP, Della Valle AG, Salvati EA. Acute sciatic nerve palsy as a delayed complication of low-molecular-weight heparin prophylaxis after total hip arthroplasty. Am J Orthop (Belle Mead NJ) 2009; 38:E28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/5\">",
"      Schmalzried TP, Noordin S, Amstutz HC. Update on nerve palsy associated with total hip replacement. Clin Orthop Relat Res 1997; :188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/6\">",
"      Nachbur B, Meyer RP, Verkkala K, Z&uuml;rcher R. The mechanisms of severe arterial injury in surgery of the hip joint. Clin Orthop Relat Res 1979; :122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/7\">",
"      Sharma DK, Kumar N, Mishra V, Howell FR. Vascular injuries in total hip replacement arthroplasty: a review of the problem. Am J Orthop (Belle Mead NJ) 2003; 32:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/8\">",
"      Wasielewski RC, Cooperstein LA, Kruger MP, Rubash HE. Acetabular anatomy and the transacetabular fixation of screws in total hip arthroplasty. J Bone Joint Surg Am 1990; 72:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/9\">",
"      Patterson BM, Healey JH, Cornell CN, Sharrock NE. Cardiac arrest during hip arthroplasty with a cemented long-stem component. A report of seven cases. J Bone Joint Surg Am 1991; 73:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/10\">",
"      Paiement GD. Prevention and treatment of venous thromboembolic disease complications in primary hip arthroplasty patients. Instr Course Lect 1998; 47:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/11\">",
"      Burnett RS, Clohisy JC, Wright RW, et al. Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty 2007; 22:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/12\">",
"      Januel JM, Chen G, Ruffieux C, et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. JAMA 2012; 307:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/13\">",
"      Pellicci PM, Bostrom M, Poss R. Posterior approach to total hip replacement using enhanced posterior soft tissue repair. Clin Orthop Relat Res 1998; :224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/14\">",
"      White RE Jr, Forness TJ, Allman JK, Junick DW. Effect of posterior capsular repair on early dislocation in primary total hip replacement. Clin Orthop Relat Res 2001; :163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/15\">",
"      Demos HA, Rorabeck CH, Bourne RB, et al. Instability in primary total hip arthroplasty with the direct lateral approach. Clin Orthop Relat Res 2001; :168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/16\">",
"      Morrey BF. Difficult complications after hip joint replacement. Dislocation. Clin Orthop Relat Res 1997; :179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/17\">",
"      Dewal H, Maurer SL, Tsai P, et al. Efficacy of abduction bracing in the management of total hip arthroplasty dislocation. J Arthroplasty 2004; 19:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/18\">",
"      Shah SN, Kaye RJ, Kelly NH, et al. Retrieval analysis of failed constrained acetabular liners. J Arthroplasty 2009; 24:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/19\">",
"      Kobayashi A, Freeman MA, Bonfield W, et al. Number of polyethylene particles and osteolysis in total joint replacements. A quantitative study using a tissue-digestion method. J Bone Joint Surg Br 1997; 79:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/20\">",
"      Drees P, Eckardt A, Gay RE, et al. Mechanisms of disease: Molecular insights into aseptic loosening of orthopedic implants. Nat Clin Pract Rheumatol 2007; 3:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/21\">",
"      Mandelin J, Li TF, Hukkanen MV, et al. Increased expression of a novel osteoclast-stimulating factor, ADAM8, in interface tissue around loosened hip prostheses. J Rheumatol 2003; 30:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/22\">",
"      Ma GF, Liljestr&ouml;m M, Ainola M, et al. Expression of ADAM9 (meltrin-gamma) around aseptically loosened total hip replacement implants. Rheumatology (Oxford) 2006; 45:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/23\">",
"      Ma G, Ainola M, Liljestr&ouml;m M, et al. Increased expression and processing of ADAM 12 (meltrin-alpha) in osteolysis associated with aseptic loosening of total hip replacement implants. J Rheumatol 2005; 32:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/24\">",
"      Mandelin J, Li TF, Hukkanen M, et al. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. J Rheumatol 2005; 32:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/25\">",
"      Walde TA, Weiland DE, Leung SB, et al. Comparison of CT, MRI, and radiographs in assessing pelvic osteolysis: a cadaveric study. Clin Orthop Relat Res 2005; :138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/26\">",
"      McCalden RW, MacDonald SJ, Rorabeck CH, et al. Wear rate of highly cross-linked polyethylene in total hip arthroplasty. A randomized controlled trial. J Bone Joint Surg Am 2009; 91:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/27\">",
"      Callaghan JJ, Cuckler JM, Huddleston JI, et al. How have alternative bearings (such as metal-on-metal, highly cross-linked polyethylene, and ceramic-on-ceramic) affected the prevention and treatment of osteolysis? J Am Acad Orthop Surg 2008; 16 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/28\">",
"      Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Relat Res 1997; :33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/29\">",
"      Arabmotlagh M, Pilz M, Warzecha J, Rauschmann M. Changes of femoral periprosthetic bone mineral density 6 years after treatment with alendronate following total hip arthroplasty. J Orthop Res 2009; 27:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/30\">",
"      Prieto-Alhambra D, Javaid MK, Judge A, et al. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ 2011; 343:d7222.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Orthopaedic Surgeons. Modern metal-on-metal hip implants: A technology overview. December 2, 2011. file://www.aaos.org/research/overviews/Metal_On_Metal.pdf (Accessed on March 29, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/32\">",
"      Griffin WL, Nanson CJ, Springer BD, et al. Reduced articular surface of one-piece cups: a cause of runaway wear and early failure. Clin Orthop Relat Res 2010; 468:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/33\">",
"      Langton DJ, Jameson SS, Joyce TJ, et al. Early failure of metal-on-metal bearings in hip resurfacing and large-diameter total hip replacement: A consequence of excess wear. J Bone Joint Surg Br 2010; 92:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/34\">",
"      Browne JA, Bechtold CD, Berry DJ, et al. Failed metal-on-metal hip arthroplasties: a spectrum of clinical presentations and operative findings. Clin Orthop Relat Res 2010; 468:2313.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Medical Devices: Metal-on-Metal Implants. file://www.fda.gov/medicaldevices/productsandmedicalprocedures/implantsandprosthetics/metalonmetalhipimplants/default.htm (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     FDA Safety Communication: Metal-on-Metal Hip Implants. file://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm335775.htm (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     MHRA Medical Device Alert MDA/2012/036 All metal-on-metal (MoM) hip replacements. file://www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON155761 (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/38\">",
"      Terefenko KM, Sychterz CJ, Orishimo K, Engh CA Sr. Polyethylene liner exchange for excessive wear and osteolysis. J Arthroplasty 2002; 17:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/39\">",
"      Rubash HE, Sinha RK, Paprosky W, et al. A new classification system for the management of acetabular osteolysis after total hip arthroplasty. Instr Course Lect 1999; 48:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/40\">",
"      Maloney WJ, Herzwurm P, Paprosky W, et al. Treatment of pelvic osteolysis associated with a stable acetabular component inserted without cement as part of a total hip replacement. J Bone Joint Surg Am 1997; 79:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/41\">",
"      Katz JN, Wright EA, Wright J, et al. Twelve-year risk of revision after primary total hip replacement in the U.S. Medicare population. J Bone Joint Surg Am 2012; 94:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/42\">",
"      Duncan CP, Masri BA. Fractures of the femur after hip replacement. Instr Course Lect 1995; 44:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/43\">",
"      Greidanus NV, Mitchell PA, Masri BA, et al. Principles of management and results of treating the fractured femur during and after total hip arthroplasty. Instr Course Lect 2003; 52:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/44\">",
"      Heck DA, Partridge CM, Reuben JD, et al. Prosthetic component failures in hip arthroplasty surgery. J Arthroplasty 1995; 10:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/45\">",
"      Galante JO. Causes of fractures of the femoral component in total hip replacement. J Bone Joint Surg Am 1980; 62:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/46\">",
"      Jazrawi LM, Della Valle CJ, Kummer FJ, et al. Catastrophic failure of a cemented, collarless, polished, tapered cobalt-chromium femoral stem used with impaction bone-grafting. A report of two cases. J Bone Joint Surg Am 1999; 81:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/47\">",
"      Chao EY, Coventry MB. Fracture of the femoral component after total hip replacement. An analysis of fifty-eight cases. J Bone Joint Surg Am 1981; 63:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/48\">",
"      Butler DR. A Minute With Malpractice. The American Academy of Orthopaedic Surgeons Bulletin; July 1995; 43:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/49\">",
"      Abraham WD, Dimon JH 3rd. Leg length discrepancy in total hip arthroplasty. Orthop Clin North Am 1992; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/50\">",
"      DeLee J, Ferrari A, Charnley J. Ectopic bone formation following low friction arthroplasty of the hip. Clin Orthop Relat Res 1976; :53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/51\">",
"      Ritter MA, Vaughan RB. Ectopic ossification after total hip arthroplasty. Predisposing factors, frequency, and effect on results. J Bone Joint Surg Am 1977; 59:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/52\">",
"      Iorio R, Healy WL. Heterotopic ossification after hip and knee arthroplasty: risk factors, prevention, and treatment. J Am Acad Orthop Surg 2002; 10:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/53\">",
"      Ahrengart L, Lindgren U. Heterotopic bone after hip arthroplasty. Defining the patient at risk. Clin Orthop Relat Res 1993; :153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/54\">",
"      Horwitz BR, Rockowitz NL, Goll SR, et al. A prospective randomized comparison of two surgical approaches to total hip arthroplasty. Clin Orthop Relat Res 1993; :154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/55\">",
"      Maloney WJ, Krushell RJ, Jasty M, Harris WH. Incidence of heterotopic ossification after total hip replacement: effect of the type of fixation of the femoral component. J Bone Joint Surg Am 1991; 73:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/56\">",
"      Nayak KN, Mulliken B, Rorabeck CH, et al. Prevalence of heterotopic ossification in cemented versus noncemented total hip joint replacement in patients with osteoarthrosis: a randomized clinical trial. Can J Surg 1997; 40:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/57\">",
"      Purtill JJ, Eng K, Rothman RH, Hozack WJ. Heterotopic ossification. Incidence in cemented versus cementless total hip arthroplasty. J Arthroplasty 1996; 11:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/58\">",
"      Wixson RL, Stulberg SD, Mehlhoff M. Total hip replacement with cemented, uncemented, and hybrid prostheses. A comparison of clinical and radiographic results at two to four years. J Bone Joint Surg Am 1991; 73:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/59\">",
"      Kjaersgaard-Andersen P, Schmidt SA, Pedersen NW, et al. Erythrocyte sedimentation rate and heterotopic bone formation after cemented total hip arthroplasty. Clin Orthop Relat Res 1989; :189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/60\">",
"      Kjaersgaard-Andersen P, Pedersen P, Kristensen SS, et al. Serum alkaline phosphatase as an indicator of heterotopic bone formation following total hip arthroplasty. Clin Orthop Relat Res 1988; :102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/61\">",
"      Brooker AF, Bowerman JW, Robinson RA, Riley LH Jr. Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am 1973; 55:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/62\">",
"      Birrell F, Lohmander S. Non-steroidal anti-inflammatory drugs after hip replacement. BMJ 2006; 333:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/63\">",
"      Fransen M, Neal B. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2004; :CD001160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/64\">",
"      Barthel T, Baumann B, N&ouml;th U, Eulert J. Prophylaxis of heterotopic ossification after total hip arthroplasty: a prospective randomized study comparing indomethacin and meloxicam. Acta Orthop Scand 2002; 73:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/65\">",
"      Saudan M, Saudan P, Perneger T, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br 2007; 89:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/66\">",
"      Roman&ograve; CL, Duci D, Roman&ograve; D, et al. Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty 2004; 19:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/67\">",
"      Amstutz HC, Fowble VA, Schmalzried TP, Dorey FJ. Short-course indomethacin prevents heterotopic ossification in a high-risk population following total hip arthroplasty. J Arthroplasty 1997; 12:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/68\">",
"      Fransen M, Anderson C, Douglas J, et al. Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ 2006; 333:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/69\">",
"      Pakos EE, Ioannidis JP. Radiotherapy vs. nonsteroidal anti-inflammatory drugs for the prevention of heterotopic ossification after major hip procedures: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 2004; 60:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/70\">",
"      Healy WL, Lo TC, DeSimone AA, et al. Single-dose irradiation for the prevention of heterotopic ossification after total hip arthroplasty. A comparison of doses of five hundred and fifty and seven hundred centigray. J Bone Joint Surg Am 1995; 77:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/71\">",
"      Gregoritch SJ, Chadha M, Pelligrini VD, et al. Randomized trial comparing preoperative versus postoperative irradiation for prevention of heterotopic ossification following prosthetic total hip replacement: preliminary results. Int J Radiat Oncol Biol Phys 1994; 30:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/72\">",
"      Lonardi F, Gioga G, Coeli M, et al. Preoperative, single-fraction irradiation for prophylaxis of heterotopic ossification after total hip arthroplasty. Int Orthop 2001; 25:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/73\">",
"      Seegenschmiedt MH, Makoski HB, Micke O, German Cooperative Group on Radiotherapy for Benign Diseases. Radiation prophylaxis for heterotopic ossification about the hip joint--a multicenter study. Int J Radiat Oncol Biol Phys 2001; 51:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/39/1658/abstract/74\">",
"      Balboni TA, Gaccione P, Gobezie R, Mamon HJ. Shielding of the hip prosthesis during radiation therapy for heterotopic ossification is associated with increased failure of prophylaxis. Int J Radiat Oncol Biol Phys 2007; 67:1499.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7973 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1658=[""].join("\n");
var outline_f1_39_1658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H239249938\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRAOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nerve injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cause",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vascular injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cause",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cement-related hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prevention and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTOPERATIVE COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Osteolysis and wear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Radiographic appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14353540\">",
"      Metal-on-metal bearing surfaces",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Aseptic loosening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Radiographic appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Periprosthetic fracture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Implant failure or fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Leg length discrepancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Heterotopic ossification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Risk factors for HO",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Physical findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Prophylaxis for HO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H239249938\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H466589287\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7973|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/34/39468\" title=\"table 1\">",
"      Surgical risk groups",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/58/12197?source=related_link\">",
"      NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=related_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/30/21987?source=related_link\">",
"      Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=related_link\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_39_1659="Indication thrombolytic therapy";
var content_f1_39_1659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential indications for thrombolytic therapy in venous thromboembolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Presence of hypotension related to PE*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of severe hypoxemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substantial perfusion defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricular dysfunction associated with PE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extensive deep vein thrombosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This indication is widely accepted; the other potential indications require careful review of relative contraindications to thrombolytic therapy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1659=[""].join("\n");
var outline_f1_39_1659=null;
var title_f1_39_1660="Potential toxicity herbs";
var content_f1_39_1660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cautions about herbs and dietary supplements when used in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Product",
"        <strong>",
"         purity",
"        </strong>",
"        is questionable; there is potential for misidentification and contamination with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Pesticides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Herbicides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Pharmaceuticals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Heavy metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Excipients such as alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Particularly for products imported from developing countries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Reliability",
"        </strong>",
"        of products is uncertain; there is great variability in concentration of active ingredients within plants used, growing conditions, processing, and storage.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Effectiveness",
"        </strong>",
"        of active ingredients in children often not studied.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Safety and toxicity for short-term",
"        </strong>",
"        use in children is often unknown.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Safety and toxicity for chronic use",
"        </strong>",
"        in children is often unknown.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown",
"        <strong>",
"         interactions",
"        </strong>",
"        with other medications and treatments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown",
"        <strong>",
"         metabolism",
"        </strong>",
"        in children with renal, hepatic, and other disorders.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cost",
"        </strong>",
"        of products is not necessarily related to quality, purity, or concentration of active ingredients.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1660=[""].join("\n");
var outline_f1_39_1660=null;
var title_f1_39_1661="DBA physical findings";
var content_f1_39_1661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical exam findings in Diamond-Blackfan anemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Craniofacial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hypertelorism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Microcephaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Congenital cataracts/glaucoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Strabismus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Microophthalmos",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Blue sclera",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            High arched palate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ear malformations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Neck",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Fusion of the vertebrae with flaring of the trapezius muscle (Turner like appearance)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Elevation of the scapula (Sprengel deformity)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Thumb",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bifid thumb",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Duplication",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Subluxation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hypoplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Absence",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Flat hypoplastic thenar eminence",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Weak/absent radial pulses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Triphalangeal thumb*",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Urogenital",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Dysplastic or horseshoe kidney",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Duplication of the ureters",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Renal tubular acidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Cardiopulmonary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ventricular and atrial septal defects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypogonadism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mental retardation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other skeletal abnormalities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other anomalies",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Triphalangeal thumbs are a characteristic of Aase syndrome, which is probably a variant of Diamond-Blackfan anemia.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Alter, BP, Young, NS. The Bone Marrow Failure Syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan, DG, Orkin, SH (Eds), W.B. Saunders Company, 1998, p.237.",
"       </li>",
"       <li>",
"        Halperin, DS, Freedman, MH, Am J Pediatr Hematol Oncol 1989; 11:380.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1661=[""].join("\n");
var outline_f1_39_1661=null;
var title_f1_39_1662="RADAR acronym for pediatricians";
var content_f1_39_1662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric screening for intimate partner violence - RADAR acronym",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        <span class=\"red\">",
"         R",
"        </span>",
"        = routinely screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Although many women who are victims of domestic violence will not volunteer any information, many will acknowledge that they are victims if asked. Intervening on behalf of battered women is an active form of preventing child abuse. Always interview the parent alone if the child is older than two years.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        <span class=\"red\">",
"         A",
"        </span>",
"        = ask direct questions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        \"Because violence is so common in many people's lives and witnessing violence can have negative effects on children, we've begun to ask all our families about their experience with violence.\" Sample questions include: \"Have you ever been harmed by or felt afraid of your partner?\" \"Have you ever been hit, kicked, punched or otherwise hurt by your partner?\" \"Do you feel unsafe in your current or a previous relationship?\" \"Have your children witnessed anything violent or frightening in their home, school or community?\" Inform parent/patients of legal reporting requirements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        <span class=\"red\">",
"         D",
"        </span>",
"        = document your findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Thoroughly document in the chart the parent/patient's description of the violence and any injuries that are present. In the case of a pediatric chart, ask the mother if it is safe to document in the child's chart. Other ways to document in the child's chart include abbreviations such as DV+ or RADAR+. If further information about the violence needs to be documented, then place details in a \"restricted access\" chart. Document what information was given to the victim and the referrals made.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        <span class=\"red\">",
"         A",
"        </span>",
"        = assess safety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Assess parent/patient safety. Help the parent/patient reduce the danger to herself and her children when the parent/patient is discharged. A safety assessment includes some of the following questions: \"Are you afraid to go home? Are there guns in the home? Are you planning on leaving? Do you need access to a shelter? Can you stay with family/friends? Has the violence increased? Have there been threats of suicide/ homicide? Use of drugs or alcohol? Violence toward children?",
"        <strong>",
"         Are your children safe?\"",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        <span class=\"red\">",
"         R",
"        </span>",
"        = review options and referrals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Refer the parent/patient to specialists trained to help victims cope with all aspects of the abuse. Take time to talk about options available to the victim and her family. Give the victim written information if she feels that it is safe to do so. Call authorities, ie, law enforcement or child protective services, if appropriate. Find safe shelter for family if needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        What to say/do with patients/parents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Domestic violence is a pattern of assaultive and coercive behaviors that adults/adolescents use against their intimate partners. Children who witness domestic violence are at an increased risk for child abuse, as well as behavioral, emotional, and psychological problems. Be aware of the reporting requirements in your state.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        DV (+) = answered 'yes' to screening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Send supportive message",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        \"You are not alone. You are not to blame. DV is a crime.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Assess safety (see above)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Make referrals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Involve social worker/advocate if needed/available. Schedule follow-up appointment for victim/children. Encourage victim/children to see their physician. Consider mental health referral for victim/children. Notify child protective services if meets criteria of commission of DV in the presence of a child. Notify law enforcement if appropriate. Give DV hotline numbers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Make follow-up appointment for victim/children. Ask about history of violence since last visit. Ask victim/children if they have seen their health care provider. Ask how children are functioning at home and at school. Ensure that children are safe. Ensure victim has resource numbers and information.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        DV(-) = answered 'no' to all questions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Accept the woman's response. Provide an open door to resources. \"I am glad that you are in a safe situation. If you ever feel unsafe you can come to us for help.\" Rescreen yearly or if risk factors occur.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        DV (?) = unable to screen or concerned",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        If the healthcare provider has a concern, then redirect the question. Provide open door to resources. \"I am glad that you are in a safe situation. If you ever feel unsafe you can come to us for help.\" Rescreen at next visit if needed. Continue to be supportive.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"2\">",
"        Domestic violence information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        National domestic violence number",
"       </td>",
"       <td>",
"        800.799.SAFE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        State DV hotline number",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        State rape crisis number",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Child protective services",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adult protective services",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Police",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Legal aid",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Other resources:",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DV: Domestic violence (intimate partner violence).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Institute for Safe Families and the PA Chapter, American Academy of Pediatrics. RADAR Pocket Card for Pediatricians. Philadelphia, PA 2002. Copyright &copy;2002 Institute for Safe Families.",
"     <br>",
"      RADAR acronym developed by the Massachusetts Medical Society.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1662=[""].join("\n");
var outline_f1_39_1662=null;
var title_f1_39_1663="FOLFIRI plus cetuximab for colorectal cancer";
var content_f1_39_1663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    FOLFIRI plus cetuximab chemotherapy for K-ras wild-type metastatic colorectal cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cetuximab",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        The appropriate dose should be withdrawn from the vials (supplied in a concentration of 2 mg/mL) and aseptically transferred into an empty sterile IV bag without further dilution. The initial dose should be infused over 120 minutes*",
"        <sup>",
"         &bull;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cetuximab",
"        </strong>",
"       </td>",
"       <td>",
"        250 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        If Day 1 cetuximab is tolerated, subsequent doses may be administered over 60 minutes.",
"       </td>",
"       <td>",
"        Weekly, beginning Day 8",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Irinotecan",
"        </strong>",
"       </td>",
"       <td>",
"        180",
"        <sup>",
"         &loz;",
"        </sup>",
"        mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 mL 5 percent dextrose in water (D5W)",
"        <sup>",
"         &sect;",
"        </sup>",
"        and administer over 90 minutes after cetuximab; may be given concurrently with leucovorin via y-site connection.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Leucovorin",
"        </strong>",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL D5W and administer over two hours; may give concurrent with irinotecan via y-site connection.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        400 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Slow intravenous push over five minutes (administer immediately after leucovorin).",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluorouracil (FU)",
"        </strong>",
"       </td>",
"       <td>",
"        2400",
"        <sup>",
"         ������",
"        </sup>",
"        mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 500 to 1000 mL D5W and administer over 46 hours (begin immediately after FU bolus). To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL normal saline.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE (30 to 60 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with diphenhydramine with or without a glucocorticoid at least prior to the first infusion of cetuximab",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors is not justified (risk of febrile neutropenia with this regimen was 3 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of FU and irinotecan may be needed for patients with liver impairment. A lower starting dose of irinotecan may be needed for patients with severe renal impairment. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        &nbsp;",
"        <span style=\"font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Irinotecan is associated with early and late diarrhea, both of which may be severe. For patients who develop abdominal cramps and/or diarrhea within 24 hours of treatment, administer atropine (0.3 to 0.6 mg IV) and premedicate with atropine during later cycles. Patients must be instructed in the early use of loperamide as a treatment for late diarrhea.",
"        </span>",
"        <strong>",
"         NOTE:",
"        </strong>",
"        <span style=\"font-family: calibri,sans-serif; font-size: 11pt;\">",
"         Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency",
"        </span>",
"        . Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Obtain CBC with differential and platelet count prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes (including magnesium, calcium, and potassium) and liver and renal function prior to each dose. Monitor serum calcium, magnesium, and potassium levels weekly for eight weeks after completion of therapy",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Patients who develop diarrhea should be closely monitored and supportive care measures (eg, fluid and electrolyte replacement, loperamide, antibiotics, etc) provided as needed. Do not retreat until resolution of diarrhea for at least 24 hours without anti-diarrheal medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Delay treatment until absolute neutrophil count is &gt;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and the platelet count is &gt;100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . US FDA-approved manufacturer's package insert suggests irinotecan dose reduction for grade 3 or worse hematologic toxicity during a prior cycle",
"        <sup>",
"         [2]",
"        </sup>",
"        . A different approach is used by some clinicians. If treatment is delayed for two weeks or delayed for one week on two separate occasions, the Day 1 FU bolus is eliminated. With the second occurrence, reduce the FU infusion dose by 20 percent and reduce irinotecan dose to 150 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Diarrhea:",
"        </strong>",
"        Withhold treatment until resolution of diarrhea for at least 24 hours off antidiarrheal medications. Reduce irinotecan dose for patients with grade 2 or worse diarrhea during a prior treatment cycle",
"        <sup>",
"         [2]",
"        </sup>",
"        . Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dermatologic toxicity:",
"        </strong>",
"        Severe dermatologic reactions, such as acneiform rash, require delayed administration of cetuximab and/or dose reduction. Refer to UpToDate topic on \"",
"        <span class=\"emphasis\">",
"         Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"        </span>",
"        \".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        If grade 2, hold treatment until less than or equal to grade 1; if grade 3 or 4, hold treatment until less than or equal to grade 2",
"        <sup>",
"         [2]",
"        </sup>",
"        . Withhold FU for grade 2 or worse diarrhea, and restart at a lower dose after complete resolution",
"        <sup>",
"         [4]",
"        </sup>",
"        . Reduce irinotecan dose for patients with grade 3 or worse other non-hematologic toxicities during a prior treatment cycle",
"        <sup>",
"         [2]",
"        </sup>",
"        . For grade 3 mucositis, eliminate FU bolus dose; prophylactic ice chips may be beneficial.&nbsp;Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count.",
"     <br>",
"      * Cetuximab should be administered with an infusion or syringe pump, using a low protein-binding 0.22 micron in line filter. Do not shake or dilute. Flush line with normal saline.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       A slower infusion rate should be considered in areas with a high incidence of infusion reactions (such as the Southeast United States). Refer to UpToDate topic on \"Infusion reactions to the therapeutic monoclonal antibodies used in cancer therapy\".",
"       <br>",
"        &Delta; Results from a nonrandomized phase II trial",
"        <sup>",
"         [5]",
"        </sup>",
"        and a multicenter retrospective analysis",
"        <sup>",
"         [6]",
"        </sup>",
"        suggest that cetuximab at a dose of 500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        every two weeks results in similar plasma concentrations and single-agent activity as does weekly dosing.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         A lower initial starting dose of irinotecan is recommended for age &ge;65, poor performance status, prior pelvic or abdominal radiotherapy, or elevated bilirubin. Whether a reduced starting dose is needed in patients who are homozygous for the UGT 1A1*28 allele (Gilbert's syndrome) and whether testing for this allele should be carried out prior to starting irinotecan is controversial. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"         <br>",
"          &sect; Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"          <br>",
"           &yen; Leucovorin dose is given for d,l-racemic mixture",
"           <sup>",
"            [7]",
"           </sup>",
"           . Use half the dose for LEVOleucovorin (l-leucovorin).",
"           <br>",
"            &Dagger; If there is no grade 1 or worse toxicity 1 in cycles 1 and 2, some clinicians increase the dose to 3000 mg/m",
"            <sup>",
"             2",
"            </sup>",
"            starting with cycle 3",
"            <sup>",
"             [1]",
"            </sup>",
"            .",
"            <br/>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Van Cutsem E, et al. N Engl J Med 2009; 360:1408.",
"       </li>",
"       <li>",
"        Camptosar (irinotecan hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).",
"       </li>",
"       <li>",
"        Erbitux (cetuximab) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).",
"       </li>",
"       <li>",
"        Fluorouracil injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).",
"       </li>",
"       <li>",
"        Pfeiffer P, et al. Ann Oncol 2008; 19:1141.",
"       </li>",
"       <li>",
"        Bouchahda M, et al. Med oncol 2011; 28 Suppl1:253.",
"       </li>",
"       <li>",
"        Leucovorin calcium injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 14, 2012).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_39_1663=[""].join("\n");
var outline_f1_39_1663=null;
